<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2024-2992</article-id><article-id custom-type="edn" pub-id-type="custom">BZBLMS</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2992</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>THERAPY GUIDELINES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ</subject></subj-group></article-categories><title-group><article-title>Evidence-based pharmacotherapy in cardiology. National guideline</article-title><trans-title-group xml:lang="ru"><trans-title>Доказательная фармакотерапия в кардиологии. Национальное руководство</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7717-4362</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марцевич Сергей Юрьевич </p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey Yu. Martsevich</p><p>Moscow</p></bio><email xlink:type="simple">sergeymartsevich@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6395-2584</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутишенко</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutishenko</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кутишенко Наталья Петровна, руководитель лаборатории фармакоэпидемиологических исследований отдела профилактической фармакотерапии</p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia P. Kutishenko</p><p>Moscow</p></bio><email xlink:type="simple">nkutishenko@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8252-3099</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукина</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukina</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лукина Юлия Владимировна </p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">yuvlu@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6035-9187</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якусевич</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakusevich</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Якусевич Владимир Валентинович </p><p>Москва</p></bio><bio xml:lang="en"><p>Vladimir V. Yakusevich</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0160-0158</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толпыгина</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolpygina</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Толпыгина Светлана Николаевна </p><p>Москва</p></bio><bio xml:lang="en"><p>Svetlana N. Tolpygina</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9320-1503</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самородская</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Samorodskaya</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самородская Ирина Владимировна </p><p>Москва</p></bio><bio xml:lang="en"><p>Irina V. Samorodskaya</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5784-4525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянов</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyanov</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лукьянов Михаил Михайлович </p><p>Москва</p></bio><bio xml:lang="en"><p>Michail M. Loukianov</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1493-4544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загребельный</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagrebelny</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загребельный Александр Васильевич </p><p>Москва</p></bio><bio xml:lang="en"><p>Alexander V. Zagrebelnyy</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8665-9129</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Метельская</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Metelskaya</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Метельская Виктория Алексеевна </p><p>Москва</p></bio><bio xml:lang="en"><p>Victoria A. Metelskaya</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9155-9189</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поддубская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Poddubskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поддубская Елена Александровна </p><p>Москва</p></bio><bio xml:lang="en"><p>Elena A. Poddubskaya</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна </p><p>Москва</p></bio><bio xml:lang="en"><p>Oxana M. Drapkina</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр терапии и профилактической медицины Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>29</day><month>03</month><year>2024</year></pub-date><volume>20</volume><issue>1</issue><fpage>105</fpage><lpage>170</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Martsevich S.Y., Kutishenko N.P., Lukina Y.V., Yakusevich V.V., Tolpygina S.N., Samorodskaya I.V., Lukyanov M.M., Zagrebelny A.V., Metelskaya V.A., Poddubskaya E.A., Drapkina O.M., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., Якусевич В.В., Толпыгина С.Н., Самородская И.В., Лукьянов М.М., Загребельный А.В., Метельская В.А., Поддубская Е.А., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Martsevich S.Y., Kutishenko N.P., Lukina Y.V., Yakusevich V.V., Tolpygina S.N., Samorodskaya I.V., Lukyanov M.M., Zagrebelny A.V., Metelskaya V.A., Poddubskaya E.A., Drapkina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2992">https://www.rpcardio.online/jour/article/view/2992</self-uri><abstract><p>.</p></abstract><trans-abstract xml:lang="ru"><p>Доказательная фармакотерапия является частью доказательной медицины и использует основные ее принципы, но только те из них, которые имеют отношение к лекарственным препаратам. Также незыблемым условием доказательной фармакотерапии является соблюдение правил надлежащей клинической практики.</p><p>Целью данного руководства является описание основных методов доказательной фармакотерапии и объективной трактовки полученных результатов, а также особенностей применения препаратов с доказанным действием в реальной клинической практике.</p><p>Авторы данного руководства выражают надежду, что оно поможет практическим врачам грамотно трактовать результаты полученных исследований, чтобы осознанно принимать клинические решения. Руководство поможет также тем, кто планирует проводить клинические исследования, избежать при этом типичных ошибок и получить результаты, реально необходимые в клинической практике.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>доказательная фармакотерапия</kwd><kwd>кардиология</kwd><kwd>национальное руководство</kwd></kwd-group><kwd-group xml:lang="en"><kwd>evidence-based pharmacotherapy</kwd><kwd>cardiology</kwd><kwd>national guideline</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ланг Г. Ф. Болезни системы кровообращения. М., 1957: 385с.</mixed-citation><mixed-citation xml:lang="en">Lang G.F. Diseases of the circulatory system. M., 1957: 385 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130-142. DOI:10.1161/01.CIR.44.1.130.</mixed-citation><mixed-citation xml:lang="en">Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130-142. DOI:10.1161/01.CIR.44.1.130.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Есht DS, Liebeson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Supression Trial. N. Engl. J. Med. 1991;324:781-788.</mixed-citation><mixed-citation xml:lang="en">Есht DS, Liebeson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Supression Trial. N. Engl. J. Med. 1991;324:781-788.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">The Israeli SPRINT Study Group. The Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-64.</mixed-citation><mixed-citation xml:lang="en">The Israeli SPRINT Study Group. The Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-64.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study Arch Intern Med. 1993;153:345-53.</mixed-citation><mixed-citation xml:lang="en">Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study Arch Intern Med. 1993;153:345-53.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison J, Kulkarni K, Baguneid M, et al. Oxford Handbook of Key Clinical Evidence. Oxford University Press, Oxford. 2010:1-3.</mixed-citation><mixed-citation xml:lang="en">Harrison J, Kulkarni K, Baguneid M, et al. Oxford Handbook of Key Clinical Evidence. Oxford University Press, Oxford. 2010:1-3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71-2. DOI:10.1136/bmj.312.7023.71.</mixed-citation><mixed-citation xml:lang="en">Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71-2. DOI:10.1136/bmj.312.7023.71.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt GH: Evidence-based medicine. ACP Journal Club. 1991, 114:A16. DOI:10.7326/ACPJC-1991-114-2-A16.</mixed-citation><mixed-citation xml:lang="en">Guyatt GH: Evidence-based medicine. ACP Journal Club. 1991, 114:A16. DOI:10.7326/ACPJC-1991-114-2-A16.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Streptomycin in Tuberculosis Trials Committee: Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948:ii:769-782.</mixed-citation><mixed-citation xml:lang="en">Streptomycin in Tuberculosis Trials Committee: Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948:ii:769-782.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В. и др. Клинические исследования по оценке лекарственной терапии: виды, достоверность результатов, место в современной доказательной медицине. Рациональная Фармакотерапия в Кардиологии. 2021;17(2):249-255. DOI:10.20996/1819-6446-2021-04-07.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Kutishenko NP, Lukina YV, et al. Clinical Trials Evaluating Drug Therapy: Types, Reliability of Results, Place in Modern Evidence-Based Medicine. Rational Pharmacotherapy in Cardiology 2021;17(2):249-255. (In Russ.) DOI:10.20996/1819-6446-2021-04-07.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25): 1887-92. DOI:10.1056/NEJM200006223422507.</mixed-citation><mixed-citation xml:lang="en">Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25): 1887-92. DOI:10.1056/NEJM200006223422507.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000; 139: S166-70. DOI:10.1161/CIRCULATIONAHA.119.040214.</mixed-citation><mixed-citation xml:lang="en">Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000; 139: S166-70. DOI:10.1161/CIRCULATIONAHA.119.040214.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Garattini S, Bertele’ V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 2007; 370: 1875–77. DOI:10.1016/S0140-6736(07)61604-3.</mixed-citation><mixed-citation xml:lang="en">Garattini S, Bertele’ V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 2007; 370: 1875–77. DOI:10.1016/S0140-6736(07)61604-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. DOI:10.1056/NEJMoa0905561.</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. DOI:10.1056/NEJMoa0905561.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. DOI:10.1056/NEJMoa1009638.</mixed-citation><mixed-citation xml:lang="en">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. DOI:10.1056/NEJMoa1009638.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-992. DOI:10.1056/NEJMoa1107039.</mixed-citation><mixed-citation xml:lang="en">Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-992. DOI:10.1056/NEJMoa1107039.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jaillon P. Controlled randomized clinical trials. Bull Acad Natl Med 2007;191: 739-56.</mixed-citation><mixed-citation xml:lang="en">Jaillon P. Controlled randomized clinical trials. Bull Acad Natl Med 2007;191: 739-56.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rief W, Hofmann SG. The limitations of equivalence and non-inferiority trials. Psychol Med. 2019;49(2):349-350. DOI:10.1017/S0033291718002891.</mixed-citation><mixed-citation xml:lang="en">Rief W, Hofmann SG. The limitations of equivalence and non-inferiority trials. Psychol Med. 2019;49(2):349-350. DOI:10.1017/S0033291718002891.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Attard N, Totton N, Gillies K, Goulao B. How do we know a treatment is good enough? A survey of non-inferiority trials. Trials. 2022;23(1):1021. DOI:10.1186/s13063-022-06911-8.</mixed-citation><mixed-citation xml:lang="en">Attard N, Totton N, Gillies K, Goulao B. How do we know a treatment is good enough? A survey of non-inferiority trials. Trials. 2022;23(1):1021. DOI:10.1186/s13063-022-06911-8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Leung JT, Barnes SL, Lo ST, Leung DY. Non-inferiority trials in cardiology: what clinicians need to know. Heart. 2020;106(2):99-104. DOI:10.1136/heartjnl-2019-315772.</mixed-citation><mixed-citation xml:lang="en">Leung JT, Barnes SL, Lo ST, Leung DY. Non-inferiority trials in cardiology: what clinicians need to know. Heart. 2020;106(2):99-104. DOI:10.1136/heartjnl-2019-315772.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? Trials. 2018;19(1):499. DOI:10.1186/s13063-018-2885-z.</mixed-citation><mixed-citation xml:lang="en">Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? Trials. 2018;19(1):499. DOI:10.1186/s13063-018-2885-z.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kim KS, Chan AW, Belley-Côté EP, Drucker AM. Noninferiority Randomized Controlled Trials. J Invest Dermatol. 2022;142(7):1773-1777. DOI:10.1016/j.jid.2022.04.015.</mixed-citation><mixed-citation xml:lang="en">Kim KS, Chan AW, Belley-Côté EP, Drucker AM. Noninferiority Randomized Controlled Trials. J Invest Dermatol. 2022;142(7):1773-1777. DOI:10.1016/j.jid.2022.04.015.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bai AD, Komorowski AS, Lo CKL et al. McMaster Infectious Diseases Fellow Research Group. Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review. BMC Med Res Methodol. 2021;21(1):75. DOI:10.1186/s12874-021-01260-7.</mixed-citation><mixed-citation xml:lang="en">Bai AD, Komorowski AS, Lo CKL et al. McMaster Infectious Diseases Fellow Research Group. Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review. BMC Med Res Methodol. 2021;21(1):75. DOI:10.1186/s12874-021-01260-7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Guerrera F, Renaud S, Tabbò F, Filosso PL. How to design a randomized clinical trial: tips and tricks for conduct a successful study in thoracic disease domain. J Thorac Dis. 2017;9(8):2692-2696. DOI:10.21037/jtd.2017.06.147.</mixed-citation><mixed-citation xml:lang="en">Guerrera F, Renaud S, Tabbò F, Filosso PL. How to design a randomized clinical trial: tips and tricks for conduct a successful study in thoracic disease domain. J Thorac Dis. 2017;9(8):2692-2696. DOI:10.21037/jtd.2017.06.147.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher RA. The arrangement of field experiments. J Min Agri GB 1926;33:700-725.</mixed-citation><mixed-citation xml:lang="en">Fisher RA. The arrangement of field experiments. J Min Agri GB 1926;33:700-725.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ratnani I, Fatima S, Abid MM, Surani Z, Surani S. Evidence-Based Medicine: History, Review, Criticisms, and Pitfalls. Cureus. 2023;15(2):e35266. DOI:10.7759/cureus.35266.</mixed-citation><mixed-citation xml:lang="en">Ratnani I, Fatima S, Abid MM, Surani Z, Surani S. Evidence-Based Medicine: History, Review, Criticisms, and Pitfalls. Cureus. 2023;15(2):e35266. DOI:10.7759/cureus.35266.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hart PD. Randomised controlled clinical trials. BMJ. 1991;302(6787):1271-1272.</mixed-citation><mixed-citation xml:lang="en">Hart PD. Randomised controlled clinical trials. BMJ. 1991;302(6787):1271-1272.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Amberson JB, MacMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuber. 1931;24:401-435.</mixed-citation><mixed-citation xml:lang="en">Amberson JB, MacMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuber. 1931;24:401-435.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Rivers WHR, Webber HN. The action of caffeine on the capacity of muscular work. The Journal of Physiology. 1907. DOI:10.1113/jphysiol.1907.sp001215.</mixed-citation><mixed-citation xml:lang="en">Rivers WHR, Webber HN. The action of caffeine on the capacity of muscular work. The Journal of Physiology. 1907. DOI:10.1113/jphysiol.1907.sp001215.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: metaepidemiological study. BMJ. 2008;336:601-5. DOI:10.1136/bmj.39465.451748.AD.</mixed-citation><mixed-citation xml:lang="en">Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: metaepidemiological study. BMJ. 2008;336:601-5. DOI:10.1136/bmj.39465.451748.AD.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded endpoint (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1(2):113-9. DOI:10.3109/08037059209077502.</mixed-citation><mixed-citation xml:lang="en">Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded endpoint (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1(2):113-9. DOI:10.3109/08037059209077502.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118.</mixed-citation><mixed-citation xml:lang="en">Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zannad F, Anker SD, Byra WM, et al.; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379(14):1332-1342. DOI:10.1056/NEJMoa1808848.</mixed-citation><mixed-citation xml:lang="en">Zannad F, Anker SD, Byra WM, et al.; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379(14):1332-1342. DOI:10.1056/NEJMoa1808848.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet. 1986;327(8478):397-402. DOI:10.1016/S0140-6736(86)92368-8.</mixed-citation><mixed-citation xml:lang="en">Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet. 1986;327(8478):397-402. DOI:10.1016/S0140-6736(86)92368-8.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337-43. DOI:10.1136/bmj.316.7141.1337.</mixed-citation><mixed-citation xml:lang="en">Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337-43. DOI:10.1136/bmj.316.7141.1337.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П. Исследование КАМЕЛИЯ: сравнение терапии, основанной на карведилоле и метопрололе, у больных артериальной гипертонией и избыточной массой тела и ожирением. Рациональная Фармакотерапия в Кардиологии. 2008;4(5):34-38. DOI:10.20996/1819-6446-2008-4-5-34-38.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Kutishenko NP. CAMELLIA trial: comparison in therapies based on carvedilol and metoprolol in hypertensive patients with overweight and obesity. Rational Pharmacother. Card. 2008; 4(5):34-38. (In Russ.) DOI:10.20996/1819-6446-2008-4-5-34-38.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Cox DR. Regression models and life tables (with discussion). J.R. Statist. Soc., Series B. 1972(2): 187-220. DOI:10.1111/j.2517-6161.1972.tb00899.x</mixed-citation><mixed-citation xml:lang="en">Cox DR. Regression models and life tables (with discussion). J.R. Statist. Soc., Series B. 1972(2): 187-220. DOI:10.1111/j.2517-6161.1972.tb00899.x</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Гланц С. Медикобиологическая статистика. М: Практика, 1998.</mixed-citation><mixed-citation xml:lang="en">Glants S. Medical and biological statistics. Moscow: Praktika; 1998 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt G. Determining optimal therapy randomized trials in individual patients. N Engl J Med. 1986;314:889-92. DOI:10.1056/NEJM198604033141406.</mixed-citation><mixed-citation xml:lang="en">Guyatt G. Determining optimal therapy randomized trials in individual patients. N Engl J Med. 1986;314:889-92. DOI:10.1056/NEJM198604033141406.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Metelitsa V., Kokurina EV, Martsevich SY. Individual choice and long-term administration of the antianginal drugs for secondary prevention of ischemic heart disease: problems, new approaches. Sov. Med. Rev. A. Cardiology. 1991;3:111-134.</mixed-citation><mixed-citation xml:lang="en">Metelitsa V., Kokurina EV, Martsevich SY. Individual choice and long-term administration of the antianginal drugs for secondary prevention of ischemic heart disease: problems, new approaches. Sov. Med. Rev. A. Cardiology. 1991;3:111-134.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">McDonald S, Nikles J. N-of-1 Trials in Healthcare. Healthcare (Basel). 2021;9(3):330. DOI:10.3390/healthcare9030330.</mixed-citation><mixed-citation xml:lang="en">McDonald S, Nikles J. N-of-1 Trials in Healthcare. Healthcare (Basel). 2021;9(3):330. DOI:10.3390/healthcare9030330.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Herrett E, Williamson E, Brack K, et al.; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. DOI:10.1136/bmj.n135.</mixed-citation><mixed-citation xml:lang="en">Herrett E, Williamson E, Brack K, et al.; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. DOI:10.1136/bmj.n135.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670-4. DOI:10.1136/bmj.319.7211.670.</mixed-citation><mixed-citation xml:lang="en">Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670-4. DOI:10.1136/bmj.319.7211.670.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Cuschieri S. The CONSORT statement. Saudi J Anaesth. 2019;13(Suppl 1): S27-S30. DOI:10.4103/sja.SJA_559_18.</mixed-citation><mixed-citation xml:lang="en">Cuschieri S. The CONSORT statement. Saudi J Anaesth. 2019;13(Suppl 1): S27-S30. DOI:10.4103/sja.SJA_559_18.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock S, Clayton T, Altman D. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686-89. DOI:10.1016/S0140-6736(02)08594-X.</mixed-citation><mixed-citation xml:lang="en">Pocock S, Clayton T, Altman D. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686-89. DOI:10.1016/S0140-6736(02)08594-X.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Barter P, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357:2109-22. DOI:10.1056/NEJMoa0706628.</mixed-citation><mixed-citation xml:lang="en">Barter P, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357:2109-22. DOI:10.1056/NEJMoa0706628.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-7.</mixed-citation><mixed-citation xml:lang="en">The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-7.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(8):827-839. DOI:10.1016/j.jacc.2021.06.024.</mixed-citation><mixed-citation xml:lang="en">Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(8):827-839. DOI:10.1016/j.jacc.2021.06.024.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Braunwald E. Cannon Cl’, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction: the unsatisfactory outcome endpoint. Circulation. 1992;86:683-687.</mixed-citation><mixed-citation xml:lang="en">Braunwald E. Cannon Cl’, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction: the unsatisfactory outcome endpoint. Circulation. 1992;86:683-687.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">McLeod C, Norman R, Litton E, et al. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun. 2019;16:100486. DOI:10.1016/j.conctc.2019.100486.</mixed-citation><mixed-citation xml:lang="en">McLeod C, Norman R, Litton E, et al. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun. 2019;16:100486. DOI:10.1016/j.conctc.2019.100486.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Baracaldo-Santamaría D, Feliciano-Alfonso JE, Ramirez-Grueso R, et al. Making Sense of Composite Endpoints in Clinical Research. Journal of Clinical Medicine. 2023;12(13):4371. DOI:10.3390/jcm12134371.</mixed-citation><mixed-citation xml:lang="en">Baracaldo-Santamaría D, Feliciano-Alfonso JE, Ramirez-Grueso R, et al. Making Sense of Composite Endpoints in Clinical Research. Journal of Clinical Medicine. 2023;12(13):4371. DOI:10.3390/jcm12134371.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Краткий обзор методических рекомендаций "Медицинские регистры. Роль в доказательной медицине. Рекомендации по созданию". Кардиоваскулярная терапия и профилактика. 2023;22(6):3615. DOI:10.15829/1728-8800-2023-3615. EDN: RPDYDF.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Lukina YuV, Kutishenko NP, et al. Guidelines "Medical registries. Role in evidence-based medicine. Recommendations for creation": a brief review. Cardiovascular Therapy and Prevention. 2023;22(6):3615. (In Russ.) DOI:10.15829/1728-8800-2023-3615. EDN: RPDYDF.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594-6. DOI:10.1136/bmj.330.7491.594.</mixed-citation><mixed-citation xml:lang="en">Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594-6. DOI:10.1136/bmj.330.7491.594.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9. Erratum in: Lancet. 2000;356(9232):860.</mixed-citation><mixed-citation xml:lang="en">Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9. Erratum in: Lancet. 2000;356(9232):860.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358:951-7.</mixed-citation><mixed-citation xml:lang="en">TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358:951-7.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. DOI:10.1016/S0140-6736(02)08089-3.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. DOI:10.1016/S0140-6736(02)08089-3.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554- 9. DOI:10.1001/jama.289.19.2554.</mixed-citation><mixed-citation xml:lang="en">Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554- 9. DOI:10.1001/jama.289.19.2554.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Armitage P. A statistical note on the analysis of the 1948 MRC streptomycin trial. J R Soc Med. 2016;109(8):312. DOI:10.1177/0141076816659004.</mixed-citation><mixed-citation xml:lang="en">Armitage P. A statistical note on the analysis of the 1948 MRC streptomycin trial. J R Soc Med. 2016;109(8):312. DOI:10.1177/0141076816659004.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Lindner JR. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovasc Imaging. 2010;3(2):204-11. DOI:10.1016/j.jcmg.2009.09.021.</mixed-citation><mixed-citation xml:lang="en">Lindner JR. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovasc Imaging. 2010;3(2):204-11. DOI:10.1016/j.jcmg.2009.09.021.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33(2):176-82. DOI:10.1093/eurheartj/ehr352.</mixed-citation><mixed-citation xml:lang="en">Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33(2):176-82. DOI:10.1093/eurheartj/ehr352.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">PARADISE-MI Investigators and Committees, Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction. New England Journal of Medicine. 2021;385(20):1845-1855. DOI:10.1056/NEJMoa2104508.</mixed-citation><mixed-citation xml:lang="en">PARADISE-MI Investigators and Committees, Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction. New England Journal of Medicine. 2021;385(20):1845-1855. DOI:10.1056/NEJMoa2104508.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Berwanger O, Pfeffer M, Claggett B, et al. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. Eur J Heart Fail. 2022;24(10):1918-1927. DOI:10.1002/ejhf.2663.</mixed-citation><mixed-citation xml:lang="en">Berwanger O, Pfeffer M, Claggett B, et al. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. Eur J Heart Fail. 2022;24(10):1918-1927. DOI:10.1002/ejhf.2663.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Ajufo E, Nayak A, Mehra MR. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions. JACC Basic Transl Sci. 2023 6;8(6):720-727. DOI:10.1016/j.jacbts.2023.05.004.</mixed-citation><mixed-citation xml:lang="en">Ajufo E, Nayak A, Mehra MR. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions. JACC Basic Transl Sci. 2023 6;8(6):720-727. DOI:10.1016/j.jacbts.2023.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Ozga AK, Rauch G. Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches. BMC Med Res Methodol. 2022;22(1):38. DOI:10.1186/s12874-022-01511-1.</mixed-citation><mixed-citation xml:lang="en">Ozga AK, Rauch G. Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches. BMC Med Res Methodol. 2022;22(1):38. DOI:10.1186/s12874-022-01511-1.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Hara H, van Klaveren D, Kogame N, et al. Statistical methods for composite endpoints. EuroIntervention. 2021;16(18):e1484-e1495. DOI:10.4244/EIJ-D-19-00953.</mixed-citation><mixed-citation xml:lang="en">Hara H, van Klaveren D, Kogame N, et al. Statistical methods for composite endpoints. EuroIntervention. 2021;16(18):e1484-e1495. DOI:10.4244/EIJ-D-19-00953.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Hara H, van Klaveren D, Takahashi K, et al.; GLOBAL LEADERS Trial Investigators. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circ Cardiovasc Qual Outcomes. 2020;13(8):e006660. DOI:10.1161/CIRCOUTCOMES.120.006660.</mixed-citation><mixed-citation xml:lang="en">Hara H, van Klaveren D, Takahashi K, et al.; GLOBAL LEADERS Trial Investigators. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circ Cardiovasc Qual Outcomes. 2020;13(8):e006660. DOI:10.1161/CIRCOUTCOMES.120.006660.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2016;12(10):1239-1245. DOI:10.4244/EIJY15M11_07.</mixed-citation><mixed-citation xml:lang="en">Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2016;12(10):1239-1245. DOI:10.4244/EIJY15M11_07.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol. 2007;3(7):407-13. DOI:10.1038/ncprheum0528.</mixed-citation><mixed-citation xml:lang="en">Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol. 2007;3(7):407-13. DOI:10.1038/ncprheum0528.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Pitt B, Segal R, Martinez FA, et al, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;347: 747-52.</mixed-citation><mixed-citation xml:lang="en">Pitt B, Segal R, Martinez FA, et al, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;347: 747-52.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-7. DOI:10.1016/s0140-6736(00)02213-3.</mixed-citation><mixed-citation xml:lang="en">Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-7. DOI:10.1016/s0140-6736(00)02213-3.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365 (9454):176-86. DOI:10.1016/S0140-6736(05)17709-5.</mixed-citation><mixed-citation xml:lang="en">Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365 (9454):176-86. DOI:10.1016/S0140-6736(05)17709-5.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and ‘number needed to treat’. Kidney Int. 2007;72(7): 789-91. DOI:10.1038/sj.ki.5002432.</mixed-citation><mixed-citation xml:lang="en">Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and ‘number needed to treat’. Kidney Int. 2007;72(7): 789-91. DOI:10.1038/sj.ki.5002432.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Hopper L, Ness A, Higgins JP, et al. GISSI-Prevenzione trial. Lancet. 1999;354(9189):1557. DOI:10.1016/s0140-6736(05)76587-9.</mixed-citation><mixed-citation xml:lang="en">Hopper L, Ness A, Higgins JP, et al. GISSI-Prevenzione trial. Lancet. 1999;354(9189):1557. DOI:10.1016/s0140-6736(05)76587-9.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Yaddanapudi LN. The American Statistical Association statement on P-values explained. J Anaesthesiol Clin Pharmacol. 2016;32(4):421-423. DOI:10.4103/0970-9185.194772.</mixed-citation><mixed-citation xml:lang="en">Yaddanapudi LN. The American Statistical Association statement on P-values explained. J Anaesthesiol Clin Pharmacol. 2016;32(4):421-423. DOI:10.4103/0970-9185.194772.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Wasserstein RL, Lazar NA. The ASA’s statement on P-values: Context, process, and purpose. [Last accessed on 2016 Nov 11]; Am Stat. 2016;70:129-33. DOI:10.1080/00031305.2016.1154108.</mixed-citation><mixed-citation xml:lang="en">Wasserstein RL, Lazar NA. The ASA’s statement on P-values: Context, process, and purpose. [Last accessed on 2016 Nov 11]; Am Stat. 2016;70:129-33. DOI:10.1080/00031305.2016.1154108.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA. 1970;214(7):1303-13.</mixed-citation><mixed-citation xml:lang="en">The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA. 1970;214(7):1303-13.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Schulz K. Randomised trials, human nature, and reporting guidelines. Lancet 1996;348:596-98.</mixed-citation><mixed-citation xml:lang="en">Schulz K. Randomised trials, human nature, and reporting guidelines. Lancet 1996;348:596-98.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152-61. DOI:10.1016/S0140-6736(08)61930-3.</mixed-citation><mixed-citation xml:lang="en">Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152-61. DOI:10.1016/S0140-6736(08)61930-3.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И. Е., Ратова Л. Г., Колос И.П. и др. Нефропротекция в лечении больных атериальной гипертонией (Результаты исследования ИРИС) Системные гипертензии 2005(1):3-6.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Ratova LG, Kolos IP. Nephroprotection in the treatment of patients with arterial hypertension (results of the IRIS study). Systemic hypertension 2005(1):3-6. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Перова Н.В., Кутишенко Н.П. и др. Открытое клиническое исследование эффективности и безопасности нового дженерика симвастатина—симвастола. Клиническая фармакология и терапия 2005;14(3):33-36.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Perova NV, Kutishenko NP, et al. Open clinical study of the effectiveness and safety of a new generic simvastatin — Simvastol. Clinical pharmacology and therapy 2005; 14 (3):33-36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Pearson K. Report of Certain Enteric Fever Inoculation Statistics. Br Med J. 1904;2. DOI:10.1136/bmj.2.2288.1243.</mixed-citation><mixed-citation xml:lang="en">Pearson K. Report of Certain Enteric Fever Inoculation Statistics. Br Med J. 1904;2. DOI:10.1136/bmj.2.2288.1243.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Glass GV. Meta-analysis at middle age: a personal history. Res Synth Methods. 2015;6(3):221-31. DOI:10.1002/jrsm.1133.</mixed-citation><mixed-citation xml:lang="en">Glass GV. Meta-analysis at middle age: a personal history. Res Synth Methods. 2015;6(3):221-31. DOI:10.1002/jrsm.1133.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Glasser S, Duval S. Meta-Analysis. In: Glasser S., ed. Essentials of Clinical Research. University of Alabama at Birmingham AL, USA, 2008.</mixed-citation><mixed-citation xml:lang="en">Glasser S, Duval S. Meta-Analysis. In: Glasser S., ed. Essentials of Clinical Research. University of Alabama at Birmingham AL, USA, 2008.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Glass G. Primary, secondary and meta-analysis of research. Educ Res. 1976; 5:3-8.</mixed-citation><mixed-citation xml:lang="en">Glass G. Primary, secondary and meta-analysis of research. Educ Res. 1976; 5:3-8.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Chumney E, Simpson K. Methods and Design for Outcomes. American Society of Health-System Pharmacists 2006. р.228.</mixed-citation><mixed-citation xml:lang="en">Chumney E, Simpson K. Methods and Design for Outcomes. American Society of Health-System Pharmacists 2006. р.228.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016- 37. DOI:10.7326/0003-4819-117-12-1016.</mixed-citation><mixed-citation xml:lang="en">Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016- 37. DOI:10.7326/0003-4819-117-12-1016.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACEinhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-64.</mixed-citation><mixed-citation xml:lang="en">Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACEinhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-64.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Pahor M, Psaty B, Alderman M, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a metaanalysis of randomised controlled trials. Lancet. 2000;356:1949-1954.</mixed-citation><mixed-citation xml:lang="en">Pahor M, Psaty B, Alderman M, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a metaanalysis of randomised controlled trials. Lancet. 2000;356:1949-1954.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-36. DOI:10.1016/S1470-2045(10)70106-6.</mixed-citation><mixed-citation xml:lang="en">Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-36. DOI:10.1016/S1470-2045(10)70106-6.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375: 735-42.</mixed-citation><mixed-citation xml:lang="en">Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375: 735-42.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967.</mixed-citation><mixed-citation xml:lang="en">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Psaty B, Lumlay T, Furberg C, et al. Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality. Clinical practice and treatment guidelines should reflect this evidence, and future trials should use low-dose diuretics as the standard for clinically useful comparisons. JAMA. 2003;289:2534-2544.</mixed-citation><mixed-citation xml:lang="en">Psaty B, Lumlay T, Furberg C, et al. Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality. Clinical practice and treatment guidelines should reflect this evidence, and future trials should use low-dose diuretics as the standard for clinically useful comparisons. JAMA. 2003;289:2534-2544.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97(4):278-86. DOI:10.1136/hrt.2010.208751.</mixed-citation><mixed-citation xml:lang="en">Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97(4):278-86. DOI:10.1136/hrt.2010.208751.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock SJ, Stone GW. The Primary Outcome Fails — What Next? N Engl J Med. 2016;375(9):861-70. DOI:10.1056/NEJMra1510064.</mixed-citation><mixed-citation xml:lang="en">Pocock SJ, Stone GW. The Primary Outcome Fails — What Next? N Engl J Med. 2016;375(9):861-70. DOI:10.1056/NEJMra1510064.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Møller MH, Ioannidis JPA, Darmon M. Are systematic reviews and meta-analyses still useful research? We are not sure. Intensive Care Med. 2018;44(4):518- 520. DOI:10.1007/s00134-017-5039-y.</mixed-citation><mixed-citation xml:lang="en">Møller MH, Ioannidis JPA, Darmon M. Are systematic reviews and meta-analyses still useful research? We are not sure. Intensive Care Med. 2018;44(4):518- 520. DOI:10.1007/s00134-017-5039-y.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Maziarz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Stud Hist Philos Sci. 2022;91:159-167. DOI:10.1016/j.shpsa.2021.11.007.</mixed-citation><mixed-citation xml:lang="en">Maziarz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Stud Hist Philos Sci. 2022;91:159-167. DOI:10.1016/j.shpsa.2021.11.007.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Ioannidis JP. Meta-research: The art of getting it wrong. Res. Syn. Meth. 2010;1:169-184.</mixed-citation><mixed-citation xml:lang="en">Ioannidis JP. Meta-research: The art of getting it wrong. Res. Syn. Meth. 2010;1:169-184.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Mariusz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Studies in history and philosophy of science. 2022;91:159-167. DOI:10.1016/j.shpsa.2021.11.007.</mixed-citation><mixed-citation xml:lang="en">Mariusz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Studies in history and philosophy of science. 2022;91:159-167. DOI:10.1016/j.shpsa.2021.11.007.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1): 2349. DOI:10.1038/s41467-021-22446-z.</mixed-citation><mixed-citation xml:lang="en">Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1): 2349. DOI:10.1038/s41467-021-22446-z.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Casey JD, Johnson NJ, Semler MW, et al. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Ann Am Thorac Soc. 2020;17(9):1144- 1153. DOI:10.1513/AnnalsATS.202005-478SD.</mixed-citation><mixed-citation xml:lang="en">Casey JD, Johnson NJ, Semler MW, et al. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Ann Am Thorac Soc. 2020;17(9):1144- 1153. DOI:10.1513/AnnalsATS.202005-478SD.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. DOI:10.1001/jama.280.7.605.</mixed-citation><mixed-citation xml:lang="en">Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. DOI:10.1001/jama.280.7.605.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Moss AJ, Davis HT, Conrad DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150-56.</mixed-citation><mixed-citation xml:lang="en">Moss AJ, Davis HT, Conrad DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150-56.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.</mixed-citation><mixed-citation xml:lang="en">The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-S34. DOI:10.4103/sja.SJA_543_18.</mixed-citation><mixed-citation xml:lang="en">Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-S34. DOI:10.4103/sja.SJA_543_18.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Levin KA. Study design III: Cross-sectional studies. Evid Based Dent. 2006;7(1): 24-5. DOI:10.1038/sj.ebd.6400375.</mixed-citation><mixed-citation xml:lang="en">Levin KA. Study design III: Cross-sectional studies. Evid Based Dent. 2006;7(1): 24-5. DOI:10.1038/sj.ebd.6400375.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Cheng Z. Cross-Sectional Studies: Strengths, Weaknesses, and Re - commendations. Chest. 2020;158(1S):S65-S71. DOI:10.1016/j.chest.2020.03.012.</mixed-citation><mixed-citation xml:lang="en">Wang X, Cheng Z. Cross-Sectional Studies: Strengths, Weaknesses, and Re - commendations. Chest. 2020;158(1S):S65-S71. DOI:10.1016/j.chest.2020.03.012.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigues DA, Plácido AI, Tavares AB, et al. Potentially Inappropriate Medication Prescribing in Older Adults According to EU(7)-Potentially Inappropriate Medication List: A Nationwide Study in Portugal. Curr Ther Res Clin Exp. 2022;97:100681. DOI:10.1016/j.curtheres.2022.100681.</mixed-citation><mixed-citation xml:lang="en">Rodrigues DA, Plácido AI, Tavares AB, et al. Potentially Inappropriate Medication Prescribing in Older Adults According to EU(7)-Potentially Inappropriate Medication List: A Nationwide Study in Portugal. Curr Ther Res Clin Exp. 2022;97:100681. DOI:10.1016/j.curtheres.2022.100681.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet. 2002;359:341-345.</mixed-citation><mixed-citation xml:lang="en">Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet. 2002;359:341-345.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999-1008. DOI:10.1016/S0140-6736(13)61752-3.</mixed-citation><mixed-citation xml:lang="en">Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999-1008. DOI:10.1016/S0140-6736(13)61752-3.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Kay CR. The Royal College of General Practitioners’ Oral Contraception Study: some recent observations. Clin Obstet Gynaecol. 1984;11(3):759-86.</mixed-citation><mixed-citation xml:lang="en">Kay CR. The Royal College of General Practitioners’ Oral Contraception Study: some recent observations. Clin Obstet Gynaecol. 1984;11(3):759-86.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Bao Y, Bertoia ML, Lenart EB, Stampfer MJ, Willett WC, Speizer FE, Chavarro JE. Origin, Methods, and Evolution of the Three Nurses’ Health Studies. Am J Public Health. 2016;106(9):1573-81. DOI:10.2105/AJPH.2016.303338.</mixed-citation><mixed-citation xml:lang="en">Bao Y, Bertoia ML, Lenart EB, Stampfer MJ, Willett WC, Speizer FE, Chavarro JE. Origin, Methods, and Evolution of the Three Nurses’ Health Studies. Am J Public Health. 2016;106(9):1573-81. DOI:10.2105/AJPH.2016.303338.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519. DOI:10.1136/bmj.38142.554479.AE</mixed-citation><mixed-citation xml:lang="en">Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519. DOI:10.1136/bmj.38142.554479.AE</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В.И., Брагина А. Е., Тарзиманова А.И. и др. Артериальная гипертензия и неблагоприятное течение COVID-19 среди госпитализированных больных: данные когортного исследования из России. Рациональная Фармакотерапия в Кардиологии. 2023;19(1):4-10. DOI:10.20996/1819-6446-2023-01-10.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Bragina AE, Tarzimanova AI, et al. Arterial Hypertension and Severe COVID-19 in Hospitalized Patients: Data from a Cohort Study. Rational Pharmacotherapy in Cardiology 2023;19(1):4-10. (In Russ.) DOI:10.20996/1819-6446-2023-01-10.</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-82. DOI:10.1056/NEJMoa021134.</mixed-citation><mixed-citation xml:lang="en">Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-82. DOI:10.1056/NEJMoa021134.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Люберецкое исследование смертности (исследование ЛИС): факторы, влияющие на отдаленный прогноз жизни после перенесенного инфаркта миокарда. Профилактическая медицина. 2013;16(2):32-8.</mixed-citation><mixed-citation xml:lang="en">Marcevich SY, Ginzburg ML, Kutishenko NP, et al. The LIS study (Lyubertsy study of mortality in patients with acute myocardial infarction). Evaluation of the pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality rate. Preventive medicine. 2013;16(2):32-8. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Марцевич С.Ю., Гинзбург М.Л. и др. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная Фармакотерапия в Кардиологии. 2013;9(2):114-122. DOI:10.20996/1819-6446-2013-9-2-114-122.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Martsevich SYu, Ginzburg ML, et al. Lyubertsy study on mortality rate ib patients after cerebral stroke or transient ischemic attack (LIS-2). Design and medical treatment estimation. Rational Pharmacotherapy in Cardiology 2013;9(2):114-122. (In Russ.) DOI:10.20996/1819-6446-2013-9-2-114-122.</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Ahern TP, Tamimi RM, Rosner BA, Hankinson SE. Digoxin use and risk of invasive breast cancer: evidence from the Nurses’ Health Study and meta-analysis. Breast Cancer Res Treat. 2014;144:427-435. DOI:10.1007/s10549-014-2886-x.</mixed-citation><mixed-citation xml:lang="en">Ahern TP, Tamimi RM, Rosner BA, Hankinson SE. Digoxin use and risk of invasive breast cancer: evidence from the Nurses’ Health Study and meta-analysis. Breast Cancer Res Treat. 2014;144:427-435. DOI:10.1007/s10549-014-2886-x.</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Masood S. Is digoxin a breast cancer risk factor? Acute Cardiac Care, 2015,17:2,29-31. DOI:10.3109/17482941.2015.1066823.</mixed-citation><mixed-citation xml:lang="en">Masood S. Is digoxin a breast cancer risk factor? Acute Cardiac Care, 2015,17:2,29-31. DOI:10.3109/17482941.2015.1066823.</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Karasneh RA, Murray LJ, Cardwell CR. Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies. Int J Cancer. 2017;140(5):1035-1041. DOI:10.1002/ijc.30520.</mixed-citation><mixed-citation xml:lang="en">Karasneh RA, Murray LJ, Cardwell CR. Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies. Int J Cancer. 2017;140(5):1035-1041. DOI:10.1002/ijc.30520.</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. DOI:10.1016/j.ijantimicag.2020.10594932205204.</mixed-citation><mixed-citation xml:lang="en">Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. DOI:10.1016/j.ijantimicag.2020.10594932205204.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Sartwell PE, Nathanson N (eds) Epidemiologic Reviews, Vol 2. Baltimore, The Johns Hopkins University Press. 1980:136-152.</mixed-citation><mixed-citation xml:lang="en">Sartwell PE, Nathanson N (eds) Epidemiologic Reviews, Vol 2. Baltimore, The Johns Hopkins University Press. 1980:136-152.</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Pottegård A. Core concepts in pharmacoepidemiology: Fundamentals of the cohort and case-control study designs. Pharmacoepidemiol Drug Saf. 2022;31(8):817-826. DOI:10.1002/pds.5482.</mixed-citation><mixed-citation xml:lang="en">Pottegård A. Core concepts in pharmacoepidemiology: Fundamentals of the cohort and case-control study designs. Pharmacoepidemiol Drug Saf. 2022;31(8):817-826. DOI:10.1002/pds.5482.</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Schulz K, Grimes D. Case-control studies: research in reverse. Lancet. 2002:359:431–34.</mixed-citation><mixed-citation xml:lang="en">Schulz K, Grimes D. Case-control studies: research in reverse. Lancet. 2002:359:431–34.</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627–31.</mixed-citation><mixed-citation xml:lang="en">Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627–31.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039–45.</mixed-citation><mixed-citation xml:lang="en">Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039–45.</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Fuller Torrey E, Rawlings R, Yolken RH. The antecedents of psychoses: a casecontrol study of selected risk factors. Schizophr Res. 2000;46(1):17-23. DOI:10.1016/s0920-9964(99)00237-6.</mixed-citation><mixed-citation xml:lang="en">Fuller Torrey E, Rawlings R, Yolken RH. The antecedents of psychoses: a casecontrol study of selected risk factors. Schizophr Res. 2000;46(1):17-23. DOI:10.1016/s0920-9964(99)00237-6.</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Rojas-Marte G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113(8):546-550. DOI:10.1093/qjmed/hcaa206. Erratum in: QJM. 2021;null.</mixed-citation><mixed-citation xml:lang="en">Rojas-Marte G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113(8):546-550. DOI:10.1093/qjmed/hcaa206. Erratum in: QJM. 2021;null.</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Stone JH, Frigault MJ, Serling-Boyd NJ, et al.; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. DOI:10.1056/NEJMoa2028836.</mixed-citation><mixed-citation xml:lang="en">Stone JH, Frigault MJ, Serling-Boyd NJ, et al.; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. DOI:10.1056/NEJMoa2028836.</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503-1516. DOI:10.1056/NEJMoa2028700.</mixed-citation><mixed-citation xml:lang="en">Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503-1516. DOI:10.1056/NEJMoa2028700.</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726. DOI:10.1136/bmj.38947.697558.AE.</mixed-citation><mixed-citation xml:lang="en">Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726. DOI:10.1136/bmj.38947.697558.AE.</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Jenner E. An inguiry into the causes and effect of variolae vaccinae, a disease discovered in some of Western connties of England, particulary Gloucestershir and known by the name of the Cow-pox. London., Low, 1798. Springfield [Mass.]: Re-printed for Dr. Samuel Cooley, by Ashley &amp; Brewer, 1802. 116pp.</mixed-citation><mixed-citation xml:lang="en">Jenner E. An inguiry into the causes and effect of variolae vaccinae, a disease discovered in some of Western connties of England, particulary Gloucestershir and known by the name of the Cow-pox. London., Low, 1798. Springfield [Mass.]: Re-printed for Dr. Samuel Cooley, by Ashley &amp; Brewer, 1802. 116pp.</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Goodwin JS. The empirical basis for the discovery of new drugs. Persp Biol Med. 1991;35:20-36.</mixed-citation><mixed-citation xml:lang="en">Goodwin JS. The empirical basis for the discovery of new drugs. Persp Biol Med. 1991;35:20-36.</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock S, Elbourne D. Randomised trials or observational studies? Lancet. 2000;342:1907-9.</mixed-citation><mixed-citation xml:lang="en">Pocock S, Elbourne D. Randomised trials or observational studies? Lancet. 2000;342:1907-9.</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Granger CB, Pocock SJ, Gersh BJ. The need for new clinical trials of old drugs. Nat Rev Cardiol. 2023;20(2):71-72. DOI:10.1038/s41569-022-00819-1.</mixed-citation><mixed-citation xml:lang="en">Granger CB, Pocock SJ, Gersh BJ. The need for new clinical trials of old drugs. Nat Rev Cardiol. 2023;20(2):71-72. DOI:10.1038/s41569-022-00819-1.</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Gliklich RE, Dreyer NA, Leavy MB. Registries for Evaluating Patient Outcomes: A User’s Guide. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US);2014 Apr. Report No.: 13(14)-EHC111.</mixed-citation><mixed-citation xml:lang="en">Gliklich RE, Dreyer NA, Leavy MB. Registries for Evaluating Patient Outcomes: A User’s Guide. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US);2014 Apr. Report No.: 13(14)-EHC111.</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt DL, Drozda JP, Shahian DM. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise. J Am Coll Cardiol. 2015; 66(20):2230-45.</mixed-citation><mixed-citation xml:lang="en">Bhatt DL, Drozda JP, Shahian DM. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise. J Am Coll Cardiol. 2015; 66(20):2230-45.</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Медицинские регистры. Роль в доказательной медицине. Рекомендации по созданию. Методические рекомендации. М.: ООО "СилицеяПолиграф", 2023. 44 с. ISBN: 978-5-6049087-8-5. DOI:10.15829/ROPNIZ-m1-2023. EDN OCKJVC.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Lukina YuV, Kutishenko NP, et al. Medical registers. Role in evidence-based medicine. Guidelines for creation. Methodological guidelines. M.: ROPNIZ, SiliceaPoligraf, 2023. 44 p. (In Russ.) ISBN: 978-5-6049087-8-5. DOI:10.15829/ROPNIZ-m1-2023. EDN OCKJVC.</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная Терапия и Профилактика. 2021;20(2):61-6. DOI:10.15829/1728-8800-2021-2786.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovascular Therapy and Prevention. 2021;20(2):2786. (In Russ.) DOI:10.15829/1728-8800-2021-2786.</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45. DOI:10.1038/ctg.2013.13.</mixed-citation><mixed-citation xml:lang="en">Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45. DOI:10.1038/ctg.2013.13.</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Эрлих А.Д. Клинические характеристики и исходы у пациентов с острым коронарным синдромом и промежуточной фракцией выброса левого желудочка (даннаые регистра "Рекорд-3"). Сердце. 2017;16(4):246-252. DOI:10.18087/RHJ.2017.4.2369.</mixed-citation><mixed-citation xml:lang="en">Erlikh AD. Clinical charateristitics and outcomes in patients with acute coronarysyndrome and moderately reduced left ventricular ejection fraction (data from Record-3 regisry). Serdze. 2017;16(4):246-252. (In Russ.) DOI:10.18087/RHJ.2017.4.2369.</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Basu A, Unuigbe A, Masseria C. Understanding differences between what alternate propensity score methods estimate. J Manag Care Spec Pharm. 2023;29(4):391-399.</mixed-citation><mixed-citation xml:lang="en">Basu A, Unuigbe A, Masseria C. Understanding differences between what alternate propensity score methods estimate. J Manag Care Spec Pharm. 2023;29(4):391-399.</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Harris M., Taylor G., Jackson D. Clinical evidence made easy. Banbury. 2014:1- 212.</mixed-citation><mixed-citation xml:lang="en">Harris M., Taylor G., Jackson D. Clinical evidence made easy. Banbury. 2014:1- 212.</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Bakhai A., Patel S., Wang D. Blinding. In: Wang D., Bakhai A., editors. Clinical trials. A practical guide to design, analysis, and reporting. Remedica, London. 2006: 75-87.</mixed-citation><mixed-citation xml:lang="en">Bakhai A., Patel S., Wang D. Blinding. In: Wang D., Bakhai A., editors. Clinical trials. A practical guide to design, analysis, and reporting. Remedica, London. 2006: 75-87.</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Pop B, Fetica B, Blaga ML, et al. The role of medical registries, potential applications and limitations. Medicine and pharmacy reports. 2019:92(1):7-14. DOI:10.15386/cjmed-1015.</mixed-citation><mixed-citation xml:lang="en">Pop B, Fetica B, Blaga ML, et al. The role of medical registries, potential applications and limitations. Medicine and pharmacy reports. 2019:92(1):7-14. DOI:10.15386/cjmed-1015.</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. Эффективность, безопасность и отдаленные исходы применения никорандила у больных стабильной ишемической болезнью сердца по результатам рандомизированного и наблюдательного исследований. Рациональная Фармакотерапия в Кардиологии. 2019;15(5):641-8. DOI:10.20996/1819-6446-2019-15-5-641-648.</mixed-citation><mixed-citation xml:lang="en">Lukina YV, Kutishenko NP, Martsevich SY. Efficacy, Safety and Long-term Outcomes of Nicorandil Use in Patients with Stable Ischemic Heart Disease According to the Results of Randomized and Observational Studies. Rational Pharmacotherapy in Cardiology 2019;15(5):641-8. (In Russ.) DOI:10.20996/1819-6446-2019-15-5-641-648.</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018; 33(34):e213. DOI:10.3346/jkms.2018.33.e213.</mixed-citation><mixed-citation xml:lang="en">Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018; 33(34):e213. DOI:10.3346/jkms.2018.33.e213.</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Lukina YV, Kutishenko NP, Semenova YV. Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies. Contemp Clin Trials Commun. 2021;21:100743. DOI:10.1016/j.conctc.2021.100743.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Lukina YV, Kutishenko NP, Semenova YV. Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies. Contemp Clin Trials Commun. 2021;21:100743. DOI:10.1016/j.conctc.2021.100743.</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-48.</mixed-citation><mixed-citation xml:lang="en">Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-48.</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-75.</mixed-citation><mixed-citation xml:lang="en">Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-75.</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. DOI:10.1136/bmj.h2147.</mixed-citation><mixed-citation xml:lang="en">Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. DOI:10.1136/bmj.h2147.</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Smelt AF, van der Weele GM, Blom JW, et al. How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract. 2010;60(576):e305-18. doi:10.3399/bjgp10X514819.</mixed-citation><mixed-citation xml:lang="en">Smelt AF, van der Weele GM, Blom JW, et al. How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract. 2010;60(576):e305-18. doi:10.3399/bjgp10X514819.</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Roland M, Torgerson DJ. What are pragmatic trials? BMJ. 1998;316(7127):285. DOI:10.1136/bmj.316.7127.285.</mixed-citation><mixed-citation xml:lang="en">Roland M, Torgerson DJ. What are pragmatic trials? BMJ. 1998;316(7127):285. DOI:10.1136/bmj.316.7127.285.</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Mentz RJ, Hernandez AF, Berdan LG, et al. Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds. Circulation. 2016;133(9):872-80. DOI:10.1161/CIRCULATIONAHA.115.019902.</mixed-citation><mixed-citation xml:lang="en">Mentz RJ, Hernandez AF, Berdan LG, et al. Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds. Circulation. 2016;133(9):872-80. DOI:10.1161/CIRCULATIONAHA.115.019902.</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Sirkis T, Jones B, Bowden J. Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. BMC Med Res Methodol. 2022;22(1):216. DOI:10.1186/s12874-022-01691-w.</mixed-citation><mixed-citation xml:lang="en">Sirkis T, Jones B, Bowden J. Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. BMC Med Res Methodol. 2022;22(1):216. DOI:10.1186/s12874-022-01691-w.</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004;12(2- 3):136-40. DOI:10.1016/j.ctim.2004.07.043.</mixed-citation><mixed-citation xml:lang="en">Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004;12(2- 3):136-40. DOI:10.1016/j.ctim.2004.07.043.</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Casey JD, Beskow LM, Brown J, et al. Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. Lancet Respir Med. 2022;10(7):700-714. DOI:10.1016/S2213-2600(22)00044-3.</mixed-citation><mixed-citation xml:lang="en">Casey JD, Beskow LM, Brown J, et al. Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. Lancet Respir Med. 2022;10(7):700-714. DOI:10.1016/S2213-2600(22)00044-3.</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Textbook of pharmacoepidemiology. Strom BL, Kimmel SE, eds. Philadelphia, 2008, 498 p.</mixed-citation><mixed-citation xml:lang="en">Textbook of pharmacoepidemiology. Strom BL, Kimmel SE, eds. Philadelphia, 2008, 498 p.</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-9. DOI:10.1016/j.jclinepi.2004.10.016.</mixed-citation><mixed-citation xml:lang="en">Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-9. DOI:10.1016/j.jclinepi.2004.10.016.</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663. DOI:10.1016/j.tmaid.2020.101663.</mixed-citation><mixed-citation xml:lang="en">Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663. DOI:10.1016/j.tmaid.2020.101663.</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. DOI:10.1016/j.medmal.2020.03.006.</mixed-citation><mixed-citation xml:lang="en">Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. DOI:10.1016/j.medmal.2020.03.006.</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Borba MGS, Val FFA, Sampaio VS, et al.; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857. DOI:10.1001/jamanetworkopen.2020.8857.</mixed-citation><mixed-citation xml:lang="en">Borba MGS, Val FFA, Sampaio VS, et al.; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857. DOI:10.1001/jamanetworkopen.2020.8857.</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020;369:m1335. DOI:10.1136/bmj.m133532238355.</mixed-citation><mixed-citation xml:lang="en">Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020;369:m1335. DOI:10.1136/bmj.m133532238355.</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Million M, Lagier JC, Tissot-Dupont H, et al. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Rev Cardiovasc Med. 2021;22(3):1063-1072. DOI:10.31083/j.rcm2203116.</mixed-citation><mixed-citation xml:lang="en">Million M, Lagier JC, Tissot-Dupont H, et al. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Rev Cardiovasc Med. 2021;22(3):1063-1072. DOI:10.31083/j.rcm2203116.</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Casadevall A, Dragotakes Q, Johnson PW, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021;10:e69866. DOI:10.7554/eLife.69866.</mixed-citation><mixed-citation xml:lang="en">Casadevall A, Dragotakes Q, Johnson PW, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021;10:e69866. DOI:10.7554/eLife.69866.</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Garibaldi BT, Wang K, Robinson ML, et al. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. Clin Infect Dis. 2022;75(1):e516-e524. DOI:10.1093/cid/ciab1035.</mixed-citation><mixed-citation xml:lang="en">Garibaldi BT, Wang K, Robinson ML, et al. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. Clin Infect Dis. 2022;75(1):e516-e524. DOI:10.1093/cid/ciab1035.</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. DOI:10.1056/NEJMoa2016638.</mixed-citation><mixed-citation xml:lang="en">Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. DOI:10.1056/NEJMoa2016638.</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Duncan A, Halim D, El Kholy K. The RECOVERY trial: An analysis and reflection two years on. Eur J Intern Med. 2022;105:111-112. DOI:10.1016/j.ejim.2022.09.018.</mixed-citation><mixed-citation xml:lang="en">Duncan A, Halim D, El Kholy K. The RECOVERY trial: An analysis and reflection two years on. Eur J Intern Med. 2022;105:111-112. DOI:10.1016/j.ejim.2022.09.018.</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Normand ST. The RECOVERY Platform. N Engl J Med. 2021;384(8):757-758. DOI:10.1056/NEJMe2025674.</mixed-citation><mixed-citation xml:lang="en">Normand ST. The RECOVERY Platform. N Engl J Med. 2021;384(8):757-758. DOI:10.1056/NEJMe2025674.</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Mahase E. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ. 2020;369:m2512. DOI:10.1136/bmj.m2512.</mixed-citation><mixed-citation xml:lang="en">Mahase E. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ. 2020;369:m2512. DOI:10.1136/bmj.m2512.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S, Leaf DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021;397(10285):1599-1601. DOI:10.1016/S0140-6736(21)00712-1.</mixed-citation><mixed-citation xml:lang="en">Gupta S, Leaf DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021;397(10285):1599-1601. DOI:10.1016/S0140-6736(21)00712-1.</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Talukder P, Saha A, Roy S, et al. Drugs for COVID-19 Treatment: A New Challenge. Appl Biochem Biotechnol. 2023;195(6):3653-3670. DOI:10.1007/s12010-023-04439-4.</mixed-citation><mixed-citation xml:lang="en">Talukder P, Saha A, Roy S, et al. Drugs for COVID-19 Treatment: A New Challenge. Appl Biochem Biotechnol. 2023;195(6):3653-3670. DOI:10.1007/s12010-023-04439-4.</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Grilli R, Magrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355:103-06.</mixed-citation><mixed-citation xml:lang="en">Grilli R, Magrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355:103-06.</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann-Eßer W, Siering U, Neugebauer EA, et al. Guideline appraisal with AGREE II: Systematic review of the current evidence on how users handle the 2 overall assessments. PLoS One. 2017;12(3):e0174831. DOI:10.1371/journal.pone.0174831.</mixed-citation><mixed-citation xml:lang="en">Hoffmann-Eßer W, Siering U, Neugebauer EA, et al. Guideline appraisal with AGREE II: Systematic review of the current evidence on how users handle the 2 overall assessments. PLoS One. 2017;12(3):e0174831. DOI:10.1371/journal.pone.0174831.</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475.</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Yang N, Zhao W, Qi WA, et al.; TERM working group. Publishing clinical prActice GuidelinEs (PAGE): Recommendations from editors and reviewers. Chin J Traumatol. 2022;25(6):312-316. DOI:10.1016/j.cjtee.2022.06.007.</mixed-citation><mixed-citation xml:lang="en">Yang N, Zhao W, Qi WA, et al.; TERM working group. Publishing clinical prActice GuidelinEs (PAGE): Recommendations from editors and reviewers. Chin J Traumatol. 2022;25(6):312-316. DOI:10.1016/j.cjtee.2022.06.007.</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Fanaroff A, Califf R, Windecker S, et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA. 2019;321(11):1069-1080. DOI:10.1001/jama.2019.1122.</mixed-citation><mixed-citation xml:lang="en">Fanaroff A, Califf R, Windecker S, et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA. 2019;321(11):1069-1080. DOI:10.1001/jama.2019.1122.</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">van der Sand CR, Leiria TL, Kalil RA. Assessment of the adherence of cardiologists to guidelines for the treatment of atrial fibrillation. Arq Bras Cardiol. 2013;101(2):127-33. DOI:10.5935/abc.20130148.</mixed-citation><mixed-citation xml:lang="en">van der Sand CR, Leiria TL, Kalil RA. Assessment of the adherence of cardiologists to guidelines for the treatment of atrial fibrillation. Arq Bras Cardiol. 2013;101(2):127-33. DOI:10.5935/abc.20130148.</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Grol R, Dalhuijsen J, Thomas S, et eal. Attribute sofclinicalguideline sthat influence use ofguidelines in general practice: observationalstudy. BMJ.1998;317(7162):858-61. DOI:10.1136/bmj.317.7162.858.</mixed-citation><mixed-citation xml:lang="en">Grol R, Dalhuijsen J, Thomas S, et eal. Attribute sofclinicalguideline sthat influence use ofguidelines in general practice: observationalstudy. BMJ.1998;317(7162):858-61. DOI:10.1136/bmj.317.7162.858.</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care Lancet. 2003;362:1225-30. DOI:10.1016/S0140-6736(03)14546-1.</mixed-citation><mixed-citation xml:lang="en">Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care Lancet. 2003;362:1225-30. DOI:10.1016/S0140-6736(03)14546-1.</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Burgmann K, Fatio S, Jordi B, Rutishauser J. Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis Swiss Med Wkly. 2013;143:w13871. DOI:10.4414/smw.2013.13871.</mixed-citation><mixed-citation xml:lang="en">Burgmann K, Fatio S, Jordi B, Rutishauser J. Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis Swiss Med Wkly. 2013;143:w13871. DOI:10.4414/smw.2013.13871.</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Pepió Vilaubí JM, Orozco-Beltrán D, Gonçalves AQ, et al. Adherence to European clinical practice guidelines for secondary prevention of cardiovascular disease: a cohort study. Int J Environ Res Public Health 2018;15:1233. DOI:10.3390/ijerph15061233.</mixed-citation><mixed-citation xml:lang="en">Pepió Vilaubí JM, Orozco-Beltrán D, Gonçalves AQ, et al. Adherence to European clinical practice guidelines for secondary prevention of cardiovascular disease: a cohort study. Int J Environ Res Public Health 2018;15:1233. DOI:10.3390/ijerph15061233.</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Widimsky P, Toušek P, Toušek F et al. Barriers in the implementation of guidelines for acute coronary syndromes. Focus on antiplatelet therapy. Cor et Vasa Amsterdam: Elsevier Science BV, 2017, 59(3):240-245, 6 pp. ISSN 0010- 8650. DOI:10.1016/j.crvasa.2016.12.002.</mixed-citation><mixed-citation xml:lang="en">Widimsky P, Toušek P, Toušek F et al. Barriers in the implementation of guidelines for acute coronary syndromes. Focus on antiplatelet therapy. Cor et Vasa Amsterdam: Elsevier Science BV, 2017, 59(3):240-245, 6 pp. ISSN 0010- 8650. DOI:10.1016/j.crvasa.2016.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Sandouk A, Ducassé JL, Grolleau S, et al. Compliance with guidelines in patients with ST-segment elevation myocardial infarction after implementation of specific guidelines for emergency care: results of RESCA+31 registry. Arch Cardiovasc Dis. 2012;105(5):262-70. DOI:10.1016/j.acvd.2012.03.001.</mixed-citation><mixed-citation xml:lang="en">Sandouk A, Ducassé JL, Grolleau S, et al. Compliance with guidelines in patients with ST-segment elevation myocardial infarction after implementation of specific guidelines for emergency care: results of RESCA+31 registry. Arch Cardiovasc Dis. 2012;105(5):262-70. DOI:10.1016/j.acvd.2012.03.001.</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2): 203-9. DOI:10.1001/archinte.164.2.203.</mixed-citation><mixed-citation xml:lang="en">LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2): 203-9. DOI:10.1001/archinte.164.2.203.</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Tan J-YB, Liu X-L, et al. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023;13:e062158. DOI:10.1136/bmjopen-2022-062158.</mixed-citation><mixed-citation xml:lang="en">Wang T, Tan J-YB, Liu X-L, et al. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023;13:e062158. DOI:10.1136/bmjopen-2022-062158.</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Kredo T, Bernhardsson S, Machingaidze S, et al. Guide to clinical practice guidelines: the current state of play. International Journal for Quality in Health Care. 2016;28(1):122-128. DOI:10.1093/intqhc/mzv115.</mixed-citation><mixed-citation xml:lang="en">Kredo T, Bernhardsson S, Machingaidze S, et al. Guide to clinical practice guidelines: the current state of play. International Journal for Quality in Health Care. 2016;28(1):122-128. DOI:10.1093/intqhc/mzv115.</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Eagle K, Montoye C, Riba A, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2005;46:1242-8. DOI:10.1016/j.jacc.2004.12.083.</mixed-citation><mixed-citation xml:lang="en">Eagle K, Montoye C, Riba A, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2005;46:1242-8. DOI:10.1016/j.jacc.2004.12.083.</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Grol R. Has guideline development gone astray? Yes. BMJ. 2010;340:c306. DOI:10.1136/bmj.c306.</mixed-citation><mixed-citation xml:lang="en">Grol R. Has guideline development gone astray? Yes. BMJ. 2010;340:c306. DOI:10.1136/bmj.c306.</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Jørgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353-60. DOI:10.1038/bjc.2012.46.</mixed-citation><mixed-citation xml:lang="en">Jørgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353-60. DOI:10.1038/bjc.2012.46.</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009301(8):831- 41. DOI:10.1001/jama.2009.205. Erratum in: JAMA. 2009 Apr 15;301(15):1544.</mixed-citation><mixed-citation xml:lang="en">Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009301(8):831- 41. DOI:10.1001/jama.2009.205. Erratum in: JAMA. 2009 Apr 15;301(15):1544.</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Classen DC, Mermel LA. Specialty Society Clinical Practice Guidelines: time for evolution or revolution? JAMA. 2015;314:871-2. DOI:10.1001/jama.2015.7462.</mixed-citation><mixed-citation xml:lang="en">Classen DC, Mermel LA. Specialty Society Clinical Practice Guidelines: time for evolution or revolution? JAMA. 2015;314:871-2. DOI:10.1001/jama.2015.7462.</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Jureidini J, McHenry LB. The illusion of evidence based medicine BMJ. 2022;376:o702. DOI:10.1136/bmj.o702.</mixed-citation><mixed-citation xml:lang="en">Jureidini J, McHenry LB. The illusion of evidence based medicine BMJ. 2022;376:o702. DOI:10.1136/bmj.o702.</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Ioannidis JP. Why Most Published Research Findings Are False. PLoS Med. 2005;2(8):e124. DOI:10.1371/journal.pmed.0020124. Erratum in: PLoS Med. 2022;19(8):e1004085.</mixed-citation><mixed-citation xml:lang="en">Ioannidis JP. Why Most Published Research Findings Are False. PLoS Med. 2005;2(8):e124. DOI:10.1371/journal.pmed.0020124. Erratum in: PLoS Med. 2022;19(8):e1004085.</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Ioannidis JP. Why Most Clinical Research Is Not Useful. PLoS Med. 2016;13(6):e1002049. DOI:10.1371/journal.pmed.1002049.</mixed-citation><mixed-citation xml:lang="en">Ioannidis JP. Why Most Clinical Research Is Not Useful. PLoS Med. 2016;13(6):e1002049. DOI:10.1371/journal.pmed.1002049.</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. doi:10.1161/CIRCULATIONAHA.114.013748.</mixed-citation><mixed-citation xml:lang="en">Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. doi:10.1161/CIRCULATIONAHA.114.013748.</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. 1987;316:1429-1435. DOI:10.1056/NEJM198706043162301.</mixed-citation><mixed-citation xml:lang="en">The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. 1987;316:1429-1435. DOI:10.1056/NEJM198706043162301.</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Fox K, Ford I, Steg PG, et al.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16. DOI:10.1016/S0140-6736(08)61170-8.</mixed-citation><mixed-citation xml:lang="en">Fox K, Ford I, Steg PG, et al.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16. DOI:10.1016/S0140-6736(08)61170-8.</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwel P. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-86. DOI:10.1016/S0140-6736(05)17709-5.</mixed-citation><mixed-citation xml:lang="en">Rothwel P. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-86. DOI:10.1016/S0140-6736(05)17709-5.</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Stuart J. Pocock, Ph.D., and Gregg W. Stone, M.D. The Primary Outcome Fails— What Next? N Engl J Med 2016;375:861-70. DOI:10.1056/NEJMra1510064.</mixed-citation><mixed-citation xml:lang="en">Stuart J. Pocock, Ph.D., and Gregg W. Stone, M.D. The Primary Outcome Fails— What Next? N Engl J Med 2016;375:861-70. DOI:10.1056/NEJMra1510064.</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С. Ю., Кутишенко Н.П. Рандомизированные клинические исследования и наблюдательные исследования: соотношение в иерархии доказательств эффективности терапии. Рациональная фармакотерапия в кардиологии. 2016;12(5):567-573. DOI:10.20996/1819-6446-2016-12-5-567-573.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs. Rational Pharmacotherapy in Cardiology 2016;12(5):567-573. (In Russ.) DOI:10.20996/1819-6446-2016-12-5-567-573.</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Лукина Ю.В., Драпкина О.М. Основные принципы комбинированной медикаментозной терапии — фокус на межлекарственное взаимодействие. Кардиоваскулярная терапия и профилактика. 2021;20(7):3031. DOI:10.15829/1728-8800-2021-3031.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Lukina YuV, Drapkina OM. Basic principles of combination therapy: focus on drug-drug interaction. Cardiovascular Therapy and Prevention. 2021;20(7):3031. (In Russ.) DOI:10.15829/1728-8800-2021-3031.</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Baxter K, Preston CL. Stockley’s Drug Interactions. Vol 495. Pharmaceutical Press; 2010.</mixed-citation><mixed-citation xml:lang="en">Baxter K, Preston CL. Stockley’s Drug Interactions. Vol 495. Pharmaceutical Press; 2010.</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol. 2018;27;10:123-34. DOI:10.2147/CPAA.S146115.</mixed-citation><mixed-citation xml:lang="en">Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol. 2018;27;10:123-34. DOI:10.2147/CPAA.S146115.</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Romagnoli KM, Nelson SD, Hines L. Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews. BMC Med Inform Decis Mak. 2017;22:21. DOI:10.1186/s12911-017-0419-3.</mixed-citation><mixed-citation xml:lang="en">Romagnoli KM, Nelson SD, Hines L. Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews. BMC Med Inform Decis Mak. 2017;22:21. DOI:10.1186/s12911-017-0419-3.</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185-191. DOI:10.1016/S0140-6736(07)61092-7.</mixed-citation><mixed-citation xml:lang="en">Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185-191. DOI:10.1016/S0140-6736(07)61092-7.</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB, for The Pharmaceutical Care Of The Elderly In Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother. 2002;36:1675-81. DOI:10.1345/aph.1A484.</mixed-citation><mixed-citation xml:lang="en">Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB, for The Pharmaceutical Care Of The Elderly In Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother. 2002;36:1675-81. DOI:10.1345/aph.1A484.</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Hohl CM, Dankoff J, Colacone A, Afi lalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001;38: 666-71. DOI:10.1067/mem.2001.119456.</mixed-citation><mixed-citation xml:lang="en">Hohl CM, Dankoff J, Colacone A, Afi lalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001;38: 666-71. DOI:10.1067/mem.2001.119456.</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med. 2000;160(10):1409-13. DOI:10.1001/archinte.160.10.1409.</mixed-citation><mixed-citation xml:lang="en">Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med. 2000;160(10):1409-13. DOI:10.1001/archinte.160.10.1409.</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Takkouche B, Etminan M, Caamaño F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf. 2002;25(5):373-8. DOI:10.2165/00002018-200225050-00005.</mixed-citation><mixed-citation xml:lang="en">Takkouche B, Etminan M, Caamaño F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf. 2002;25(5):373-8. DOI:10.2165/00002018-200225050-00005.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Teerlink JR, Qian M, Bello NA, et al; WARCEF Investigators. Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial. JACC Heart Fail. 2017;5(8):603-610. DOI:10.1016/j.jchf.2017.04.011.</mixed-citation><mixed-citation xml:lang="en">Teerlink JR, Qian M, Bello NA, et al; WARCEF Investigators. Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial. JACC Heart Fail. 2017;5(8):603-610. DOI:10.1016/j.jchf.2017.04.011.</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Cascorbi I. Drug interactions–principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109:546-56. DOI:10.3238/arztebl.2012.0546.</mixed-citation><mixed-citation xml:lang="en">Cascorbi I. Drug interactions–principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109:546-56. DOI:10.3238/arztebl.2012.0546.</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357. DOI:10.1097/01.hjh.0000431740.32696.cc.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357. DOI:10.1097/01.hjh.0000431740.32696.cc.</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953-2041. DOI:10.1097/HJH.0000000000001940.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953-2041. DOI:10.1097/HJH.0000000000001940.</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. DOI:10.1093/eurheartj/ehaa612.</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. DOI:10.1093/eurheartj/ehaa612.</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. DOI:10.1093/eurheartj/ehz486.</mixed-citation><mixed-citation xml:lang="en">Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. DOI:10.1093/eurheartj/ehz486.</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Leal Rodríguez C, Kaas-Hansen BS, Eriksson R, et al. Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes. Pharmacoepidemiol Drug Saf. 2022;31(6):632-642. DOI:10.1002/pds.5415</mixed-citation><mixed-citation xml:lang="en">Leal Rodríguez C, Kaas-Hansen BS, Eriksson R, et al. Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes. Pharmacoepidemiol Drug Saf. 2022;31(6):632-642. DOI:10.1002/pds.5415</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Eroglu TE, Blom MT, Souverein PC, de Boer A, Tan HL. Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of outof-hospital cardiac arrest: real-world data from a population-based study. Europace. 2022;24(4):630-638. DOI:10.1093/europace/euab251.</mixed-citation><mixed-citation xml:lang="en">Eroglu TE, Blom MT, Souverein PC, de Boer A, Tan HL. Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of outof-hospital cardiac arrest: real-world data from a population-based study. Europace. 2022;24(4):630-638. DOI:10.1093/europace/euab251.</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Лукина Ю.В., Загребельный А.В. и др. Комбинированная антигипертензивная терапия в реальной клинической практике. Фокус на фиксированные комбинации антигипертензивных препаратов (по данным амбулаторных регистров РЕКВАЗА и ПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии. 2017;13(3):323-329. DOI:10.20996/1819-6446-2017-13-3-323-329.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Lukina YuV, Zagrebelnyy AV, et al. Combined antihypertensive therapy in real clinical practice. Focus on fixed combinations of antihypertensive drugs (According to the Data of Outpatient Registries RECVASA and PROFILE). Rational Pharmacotherapy in Cardiology. 2017;13(3):323-329. (In Russ.) DOI:10.20996/1819-6446-2017-13-3-323-329.</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. DOI:10.1136/bmj.326.7404.1419. Erratum in: BMJ. 2003;327(7415):586. Erratum in: BMJ. 2006;60(9):823.</mixed-citation><mixed-citation xml:lang="en">Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. DOI:10.1136/bmj.326.7404.1419. Erratum in: BMJ. 2003;327(7415):586. Erratum in: BMJ. 2006;60(9):823.</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Indian Polycap Study (TIPS); Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341-51. DOI:10.1016/S0140-6736(09)60611-5.</mixed-citation><mixed-citation xml:lang="en">Indian Polycap Study (TIPS); Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341-51. DOI:10.1016/S0140-6736(09)60611-5.</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Joseph P, Dans A, et al: International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216-228. DOI:10.1056/NEJMoa2028220.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Joseph P, Dans A, et al: International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216-228. DOI:10.1056/NEJMoa2028220.</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Castellano JM, Pocock SJ, Bhatt DL et al; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. DOI:10.1056/NEJMoa2208275.</mixed-citation><mixed-citation xml:lang="en">Castellano JM, Pocock SJ, Bhatt DL et al; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. DOI:10.1056/NEJMoa2208275.</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. и др. Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций. Методические рекомендации. Профилактическая медицина. 2020;23(3):2042-2060. DOI:10.17116/profmed20202303242.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu et al. Methodological recommendations: "Adherence to drug therapy in patients with chronic non-communicable diseases. Addressing the problem in a number of clinical situations". Profilakticheskaya Meditsina. 2020;23(32):4260. (In Russ.) DOI:10.17116/profmed20202303242.</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю. В., Кутишенко Н.П., Марцевич С. Ю. Приверженность лечению: современный взгляд на знакомую проблему. Кардиоваскулярная терапия и профилактика. 2017;16(1):91-95.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu. Treatment adherence: modern view on a well-known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-95. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Vrijens B, De Geest S, Hughes DA. et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. DOI:10.1111/j.1365-2125.2012.04167.</mixed-citation><mixed-citation xml:lang="en">Vrijens B, De Geest S, Hughes DA. et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. DOI:10.1111/j.1365-2125.2012.04167.</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1): 30-35. DOI:10.7326/M18-0543.</mixed-citation><mixed-citation xml:lang="en">De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1): 30-35. DOI:10.7326/M18-0543.</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Драпкина О.М. Разработка и валидизация новых опросников в медицине на примере шкалы приверженности лекарственной терапии. Рациональная Фармакотерапия в Кардиологии. 2021;17(4):576-583. DOI:10.20996/1819-6446-2021-08-02.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu, et al. The Questionnaire Survey Method in Medicine on the Example of Treatment Adherence Scales. Rational Pharmacotherapy in Cardiology. 2021;17(4):576-583 (In Russ.) DOI:10.20996/1819-6446-2021-08-02.</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015; 2015:217047. DOI:10.1155/2015/217047.</mixed-citation><mixed-citation xml:lang="en">Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015; 2015:217047. DOI:10.1155/2015/217047.</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. DOI:10.1056/NEJMra050100</mixed-citation><mixed-citation xml:lang="en">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. DOI:10.1056/NEJMra050100</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. и др. Опросники и шкалы для оценки приверженности к лечению — преимущества и недостатки диагностического метода в научных исследованиях и реальной клинической практике. Кардиоваскулярная терапия и профилактика. 2020;19(3):2562. DOI:10.15829/1728-8800-2020-2562.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Questionnaires and scores for assessing medication adherence — advantages and disadvantages of the diagnostic method in research and actual clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):2562. (In Russ.) DOI:10.15829/1728-8800-2020-2562.</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care. 1986;24(1):67-74. DOI:10.1097/00005650-198601000-00007.</mixed-citation><mixed-citation xml:lang="en">Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care. 1986;24(1):67-74. DOI:10.1097/00005650-198601000-00007.</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-354. DOI:10.1111/j.1751-7176.2008.07572.x.</mixed-citation><mixed-citation xml:lang="en">Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-354. DOI:10.1111/j.1751-7176.2008.07572.x.</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. DOI:10.1016/s0738-3991(98)00107-4.</mixed-citation><mixed-citation xml:lang="en">Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. DOI:10.1016/s0738-3991(98)00107-4.</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in lowliteracy patients with chronic disease. J Nurs Meas. 2007;15(3):203-19. DOI:10.1891/106137407783095757.</mixed-citation><mixed-citation xml:lang="en">Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in lowliteracy patients with chronic disease. J Nurs Meas. 2007;15(3):203-19. DOI:10.1891/106137407783095757.</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-7. DOI:10.1016/s0920-9964(99)00130-9.</mixed-citation><mixed-citation xml:lang="en">Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-7. DOI:10.1016/s0920-9964(99)00130-9.</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res. 2008;100:53-9. DOI:10.1016/j.schres.2007.10.029.</mixed-citation><mixed-citation xml:lang="en">Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res. 2008;100:53-9. DOI:10.1016/j.schres.2007.10.029.</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. DOI:10.1111/j.1524-4733.2008.00400.x.</mixed-citation><mixed-citation xml:lang="en">Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. DOI:10.1111/j.1524-4733.2008.00400.x.</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Николаев Н.А., Скирденко Ю.П., Жеребилов В.В. Количественная оценка приверженности к лечению в клинической медицине: протокол, процедура, интерпретация. Качественная клиническая практика. 2016;1:50-59.</mixed-citation><mixed-citation xml:lang="en">Nikolaev NA, Skirdenko YP, Zherebilov VV. Quantitative assessment of treatment adherence in clinical medicine: Protocol, procedure, interpretation. Quality clinical practice. 2016;1:50-59. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Фофанова Т.В., Агеев Ф. Т., Смирнова М.Д. Отечественный опросник приверженности терапии: апробация и применение в амбулаторной практике. Системные гипертензии. 2014;2:13-16.</mixed-citation><mixed-citation xml:lang="en">Fofanova TV, Ageev FT, Smirnova MD. Domestic questionnaire of adherence to therapy: testing and application in outpatient practice. Systemic hypertension. 2014;2:13-16. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Кадыров Р.В., Асриян О.Б., Ковальчук С.А. Опросник "Уровень комплаентности". Монография. Владивосток: Мор.гос. ун-т. 2014. 74 с.</mixed-citation><mixed-citation xml:lang="en">Kadyrov RV, Asriyan OB, Kovalchuk SA. Questionnaire "Compliance level". Monograph / R.V. Kadyrov, O.B. Asriyan, S.A. Kovalchuk. Vladivostok: Moscow State University, 2014. 74 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Гусейнова Э. Т., Лукина Ю. В., Кутишенко Н.П. и др. Приверженность к медикаментозной терапии и риск сердечно-сосудистых событий у пациентов с хронической сердечной недостаточностью (по данным амбулаторного регистра). Кардиоваскулярная терапия и профилактика. 2022;21(10):3389. DOI:10.15829/1728-8800-2022-3389.</mixed-citation><mixed-citation xml:lang="en">Guseinova ET, Lukina YuV, Kutishenko NP, et al. Adherence to therapy and the risk of cardiovascular events in patients with heart failure: data from the outpatient registry. Cardiovascular Therapy and Prevention. 2022;21(10):3389. (In Russ.) DOI:10.15829/1728-8800-2022-3389.</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112. DOI:10.1186/s13643-019-1014-8.</mixed-citation><mixed-citation xml:lang="en">Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112. DOI:10.1186/s13643-019-1014-8.</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011:304-14. DOI:10.4065/mcp.2010.0575.</mixed-citation><mixed-citation xml:lang="en">Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011:304-14. DOI:10.4065/mcp.2010.0575.</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Improving physician adherence to clinical practice guidelines. Barriers and strategies for change. New England Healthcare Institute, 2008, 55 p.</mixed-citation><mixed-citation xml:lang="en">Improving physician adherence to clinical practice guidelines. Barriers and strategies for change. New England Healthcare Institute, 2008, 55 p.</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and Strategies in Guideline Implementation-A Scoping Review. Healthcare (Basel). 2016;4(3):36. DOI:10.3390/healthcare4030036.</mixed-citation><mixed-citation xml:lang="en">Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and Strategies in Guideline Implementation-A Scoping Review. Healthcare (Basel). 2016;4(3):36. DOI:10.3390/healthcare4030036.</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В. Проблема выбора лекарственного препарата с позиций доказательной медицины на примере бета-адреноблокаторов. Рациональная Фармакотерапия в Кардиологии. 2010;6(6):876-881. DOI:10.20996/1819-6446-2010-6-6-876-881.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP, Lukina YuV. The choice of drug from the standpoint of evidence-based medicine: case study of beta-blockers. Rational Pharmacotherapy in Cardiology. 2010;6(6):876-881 (In Russ.) DOI:10.20996/1819-6446-2010-6-6-876-881.</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Soares I, Carneiro AV. Drug class effects: definitions and practical applications. Rev Port Cardiol. 2002;21(9):1031-42.</mixed-citation><mixed-citation xml:lang="en">Soares I, Carneiro AV. Drug class effects: definitions and practical applications. Rev Port Cardiol. 2002;21(9):1031-42.</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю. Как решить проблему выбора препарата внутри одного класса с позиций доказательной медицины? Рациональная Фармакотерапия в Кардиологии. 2019;15(2):271- 276. DOI:10.20996/1819-6446-2019-15-2-271-276.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu. How to solve the problem of drug choice within the same class from the standpoint of evidence-based medicine? Rational Pharmacotherapy in Cardiology. 2019;15(2):271-276. (In Russ.) DOI:10.20996/1819-6446-2019-15-2-271-276.</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol. 2001;37(5):1456-60. DOI:10.1016/s0735-1097(01)01161-5.</mixed-citation><mixed-citation xml:lang="en">Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol. 2001;37(5):1456-60. DOI:10.1016/s0735-1097(01)01161-5.</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer GF. History and regulatory issues of generic drugs. Transplant Proc. 1999;31(3A Suppl):10S-12S. DOI:10.1016/s0041-1345(99)00105-0.</mixed-citation><mixed-citation xml:lang="en">Meyer GF. History and regulatory issues of generic drugs. Transplant Proc. 1999;31(3A Suppl):10S-12S. DOI:10.1016/s0041-1345(99)00105-0.</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Senn S. In the blood: proposed new requirements for registering generic drugs. Lancet. 1998;352(9122):85-6. DOI:10.1016/s0140-6736(98)85007-1.</mixed-citation><mixed-citation xml:lang="en">Senn S. In the blood: proposed new requirements for registering generic drugs. Lancet. 1998;352(9122):85-6. DOI:10.1016/s0140-6736(98)85007-1.</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514-26. DOI:10.1001/jama.2008.758.</mixed-citation><mixed-citation xml:lang="en">Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514-26. DOI:10.1001/jama.2008.758.</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Manzoli L, Flacco ME, Boccia S et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351-68. DOI:10.1007/s10654-015-0104-8.</mixed-citation><mixed-citation xml:lang="en">Manzoli L, Flacco ME, Boccia S et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351-68. DOI:10.1007/s10654-015-0104-8.</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л. и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная Фармакотерапия в Кардиологии. 2012;8(2):179-184. DOI:10.20996/1819-6446-2012-8-2-54-55.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP, Ginzburg ML, et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacotherapy in Cardiology. 2012;8(2):179-184. (In Russ.) DOI:10.20996/1819-6446-2012-8-2-54-55.</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012;367(3):193-7. DOI:10.1056/NEJMp1206652.</mixed-citation><mixed-citation xml:lang="en">Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012;367(3):193-7. DOI:10.1056/NEJMp1206652.</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Вотчал Б. Е. Очерки клинической фармакологии. Медгиз. М. 1963.</mixed-citation><mixed-citation xml:lang="en">Votchal B.E. Essays on clinical pharmacology. Medgiz. M. 1963. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9. DOI:10.1016/S0140-6736(00)02799-9.</mixed-citation><mixed-citation xml:lang="en">Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9. DOI:10.1016/S0140-6736(00)02799-9.</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Герасимов В.Б., Лукьянов С.В., Бабахин А.А. и др. Побочные эффекты лекарственных средств. Ремедиум 2005;1-2:32-36.</mixed-citation><mixed-citation xml:lang="en">Gerasimov VB, Lukyanov SV, Babakhin AA, et al. Side effects of drugs. Remedium 2005;1-2:32-36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Лепахин В.К., Переверзев А.П., Романов Б.К. Cравнительная оценка количества сообщений о нежелательных реакциях на лекарственные средства. Безопасность и риск фармакотерапии. 2015;(1):30-36.</mixed-citation><mixed-citation xml:lang="en">Lepakhin VK, Pereverzev AP, Romanov BK. Comparative evaluation of information on adverse reactions to medicines. Safety and Risk of Pharmacotherapy. 2015;(1):30-36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs Stand. 2016;30(50):53-63. DOI:10.7748/ns.2016.e10214.</mixed-citation><mixed-citation xml:lang="en">Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs Stand. 2016;30(50):53-63. DOI:10.7748/ns.2016.e10214.</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Щулькин А.В., Якушева Е.Н., Попова Н.М. Pоль гликопротеина-р в рациональной фармакотерапии в кардиологии. Рациональная Фармакотерапия в Кардиологии. 2013;9(6):701-707. DOI:10.20996/1819-6446-2013-9-6-701-707.</mixed-citation><mixed-citation xml:lang="en">Shulkin AV, Yakusheva EN, Popova NM. The role of p-glycoprotein in rational pharmacotherapy in cardiology. Rational Pharmacotherapy in Cardiology. 2013;9(6):701-707. (In Russ.) DOI:10.20996/1819-6446-2013-9-6-701-707.</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Сычёв Д.А., Отделенов В.А., Денисенко Н.П. и др. Изучение активности изоферментов цитохрома Р450 для прогнозирования межлекарственных взаимодействий лекарственных средств в условиях полипрагмазии. Фармакогенетика и фармакогеномика. 2016;(2):4-11.</mixed-citation><mixed-citation xml:lang="en">Sychev DA, Otdelenov VA, Denisenko NP, et al. The study of the activity of isoenzymes of cytochrome P450 for the prediction of drug-drug interactions of medicines in terms of polypharmacy. Pharmacogenetics and Pharmacogenomics. 2016;(2):4-11. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreiro JL, Ueno M, Capodanno D et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. 2010;3(5):436-41. DOI:10.1161/CIRCINTERVENTIONS.110.957829.</mixed-citation><mixed-citation xml:lang="en">Ferreiro JL, Ueno M, Capodanno D et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. 2010;3(5):436-41. DOI:10.1161/CIRCINTERVENTIONS.110.957829.</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. DOI:10.1016/j.jacc.2012.11.019.</mixed-citation><mixed-citation xml:lang="en">O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. DOI:10.1016/j.jacc.2012.11.019.</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt DL, Cryer BL, Contant CF et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.</mixed-citation><mixed-citation xml:lang="en">Bhatt DL, Cryer BL, Contant CF et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.</mixed-citation><mixed-citation xml:lang="en">Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324(8):761-771. DOI:10.1001/jama.2020.12443.</mixed-citation><mixed-citation xml:lang="en">Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324(8):761-771. DOI:10.1001/jama.2020.12443.</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Birocchi S, Rocchetti M, Minardi A, et al. Guide antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta‐analyses of randomized controlled trials with homogeneous design. MEDRXIV. DOI:10.1101/2023.05.25.23290520.</mixed-citation><mixed-citation xml:lang="en">Birocchi S, Rocchetti M, Minardi A, et al. Guide antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta‐analyses of randomized controlled trials with homogeneous design. MEDRXIV. DOI:10.1101/2023.05.25.23290520.</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Белецкий Г.А., Кирсанов К.И., Лесовая Е.А., Якубовская М. Г. Лекарственный канцерогенез: факторы риска и возможности предотвращения. Успехи биологической химии. 2020;60:173-226.</mixed-citation><mixed-citation xml:lang="en">Beletsky GA, Kirsanov KI, Lesovaya EA, Yakubovskaya MG. Drug carcinogenesis: risk factors and prevention options. Advances in Biological Chemistry 2020; 60:173-226 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Ослопов В.Н., Макаров М.А., Борисов Д.В. Риск развития злокачественных новообразований при приеме различных классов антигипертензивных препаратов. Практическая медицина. 2013;(3):30-33.</mixed-citation><mixed-citation xml:lang="en">Оslopov VN, Makarov MA, Borisov DV. The risk of malignant neoplasms development at the intake of different classes of antihypertensive drugs. Practical Medicine. 2013;(3):30-33. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74-80. DOI:10.1001/jama.295.1.74.</mixed-citation><mixed-citation xml:lang="en">Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74-80. DOI:10.1001/jama.295.1.74.</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Marelli C, Gunnarsson C, Ross S, et al. Statins and Risk of Cancer: A Retrospective Cohort Analysis of 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult Americans. J Am Coll Cardiol. 2011;58(5):530-537. DOI:10.1016/j.jacc.2011.04.015.</mixed-citation><mixed-citation xml:lang="en">Marelli C, Gunnarsson C, Ross S, et al. Statins and Risk of Cancer: A Retrospective Cohort Analysis of 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult Americans. J Am Coll Cardiol. 2011;58(5):530-537. DOI:10.1016/j.jacc.2011.04.015.</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Баранова Е.И. Антигипертензивная терапия антагонистами рецепторов ангиотензина II и риск развития злокачественных новообразований. Артериальная гипертензия 2012;18(5):375-384. DOI:10.18705/1607-419X-2012-18-5-375-384.</mixed-citation><mixed-citation xml:lang="en">Baranova EI. Antihypertensive therapy with angiotensin II receptor blockers and risk of cancer. "Arterial’naya Gipertenziya" ("Arterial Hypertension") 2012;18(5):375-384. (In Russ.) DOI:10.18705/1607-419X-2012-18-5-375-384.</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Sipahi I. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials. PLoS One 2022;17(3):e0263461. DOI:10.1371/journal.pone.0263461.</mixed-citation><mixed-citation xml:lang="en">Sipahi I. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials. PLoS One 2022;17(3):e0263461. DOI:10.1371/journal.pone.0263461.</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Н.В., Упницкий А.А. Побочные эффекты лекарственных средств и методы их выявления. Лечебное дело 2007;1:3-11.</mixed-citation><mixed-citation xml:lang="en">Voronina NV, Upnitsky AA. Side effects of drugs and methods for their detection. Lechebnoe delo. 2007;1:3-11. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Якусевич В.В. Доказательная медицина: очевидные достоинства и скрытые недостатки. Гепатология и гастроэнтерология 2023;7(1):6-14. DOI:10.25298/2616-5546-2023-7-1-6-14.</mixed-citation><mixed-citation xml:lang="en">Yakusevich VV. Evidence-based medicine: obvious obvious benefits and hidden drawbacks. Hepatology and gastroenterology 2023;7(1):6-14. (In Russ) DOI:10.25298/2616-5546-2023-7-1-6-14.</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Ghose K. Hospital bed occupancy due to drug-related problems. J R Soc Med. 1980;73(12):853-6. DOI:10.1177/014107688007301207.</mixed-citation><mixed-citation xml:lang="en">Ghose K. Hospital bed occupancy due to drug-related problems. J R Soc Med. 1980;73(12):853-6. DOI:10.1177/014107688007301207.</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2021;43(3):726-730. DOI:10.1007/s11096-020-01150-w.</mixed-citation><mixed-citation xml:lang="en">Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2021;43(3):726-730. DOI:10.1007/s11096-020-01150-w.</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">van Mil JW, Westerlund LO, Hersberger KE et al. Drug-related problem classification systems. Ann Pharmacother. 2004;38(5):859-67. DOI:10.1345/aph.1D182.</mixed-citation><mixed-citation xml:lang="en">van Mil JW, Westerlund LO, Hersberger KE et al. Drug-related problem classification systems. Ann Pharmacother. 2004;38(5):859-67. DOI:10.1345/aph.1D182.</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">van den Bemt PM, Egberts TC, de Jong-van den Berg LT et al. Drugrelated problems in hospitalised patients. Drug Saf. 2000;22(4):321-33. DOI:10.2165/00002018-200022040-00005.</mixed-citation><mixed-citation xml:lang="en">van den Bemt PM, Egberts TC, de Jong-van den Berg LT et al. Drugrelated problems in hospitalised patients. Drug Saf. 2000;22(4):321-33. DOI:10.2165/00002018-200022040-00005.</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Gayathri B, Emily Divasish L, Soni M, et al. Drug related problems: a systemic literature review. Indo American Journal of Pharmaceutical Sciences. 2018;05(03):1409-1415. DOI:10.5281/zenodo.1198191.</mixed-citation><mixed-citation xml:lang="en">Gayathri B, Emily Divasish L, Soni M, et al. Drug related problems: a systemic literature review. Indo American Journal of Pharmaceutical Sciences. 2018;05(03):1409-1415. DOI:10.5281/zenodo.1198191.</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Saldanha V, Araújo IBd, Lima SIVC, et al. Risk factors for drug-related problems in a general hospital: A large prospective cohort. PLOS ONE. 2020;15(5):e0230215. DOI:10.1371/journal.pone.0230215.</mixed-citation><mixed-citation xml:lang="en">Saldanha V, Araújo IBd, Lima SIVC, et al. Risk factors for drug-related problems in a general hospital: A large prospective cohort. PLOS ONE. 2020;15(5):e0230215. DOI:10.1371/journal.pone.0230215.</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Amankwa Harrison M, Marfo AFA, Buabeng KO, et al. Drug-related problems among hospitalized hypertensive and heart failure patients and physician acceptance of pharmacists’ interventions at a teaching hospital in Ghana. Health Sci Rep. 2022;5(5):e786. DOI:10.1002/hsr2.786.</mixed-citation><mixed-citation xml:lang="en">Amankwa Harrison M, Marfo AFA, Buabeng KO, et al. Drug-related problems among hospitalized hypertensive and heart failure patients and physician acceptance of pharmacists’ interventions at a teaching hospital in Ghana. Health Sci Rep. 2022;5(5):e786. DOI:10.1002/hsr2.786.</mixed-citation></citation-alternatives></ref><ref id="cit286"><label>286</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufmann CP, Stämpfli D, Mory N, et al. Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems. BMJ Open. 2018;8:e016610. DOI:10.1136/bmjopen-2017-016610.</mixed-citation><mixed-citation xml:lang="en">Kaufmann CP, Stämpfli D, Mory N, et al. Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems. BMJ Open. 2018;8:e016610. DOI:10.1136/bmjopen-2017-016610.</mixed-citation></citation-alternatives></ref><ref id="cit287"><label>287</label><citation-alternatives><mixed-citation xml:lang="ru">Stämpfli D, Boeni F, Gerber A, et al. Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalized older patients according to their risk of drug-related problems: a cross-sectional validation study. BMJ Open. 2018;8:e021284. DOI:10.1136/bmjopen-2017-021284.</mixed-citation><mixed-citation xml:lang="en">Stämpfli D, Boeni F, Gerber A, et al. Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalized older patients according to their risk of drug-related problems: a cross-sectional validation study. BMJ Open. 2018;8:e021284. DOI:10.1136/bmjopen-2017-021284.</mixed-citation></citation-alternatives></ref><ref id="cit288"><label>288</label><citation-alternatives><mixed-citation xml:lang="ru">Sakthong P, Jaisue P. Impact of a drug-related patient-reported outcome measure on drug-related problem identification, physicians’ acceptance, and clinical and quality of life outcomes: a randomized controlled trial. Int J Clin Pharm. 2022;44(2):320-329. DOI:10.1007/s11096-021-01341-z.</mixed-citation><mixed-citation xml:lang="en">Sakthong P, Jaisue P. Impact of a drug-related patient-reported outcome measure on drug-related problem identification, physicians’ acceptance, and clinical and quality of life outcomes: a randomized controlled trial. Int J Clin Pharm. 2022;44(2):320-329. DOI:10.1007/s11096-021-01341-z.</mixed-citation></citation-alternatives></ref><ref id="cit289"><label>289</label><citation-alternatives><mixed-citation xml:lang="ru">Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. Drug Saf. 2006;29(11):1011-22. DOI:10.2165/00002018-200629110-00001.</mixed-citation><mixed-citation xml:lang="en">Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. Drug Saf. 2006;29(11):1011-22. DOI:10.2165/00002018-200629110-00001.</mixed-citation></citation-alternatives></ref><ref id="cit290"><label>290</label><citation-alternatives><mixed-citation xml:lang="ru">Ramadanov N, Klein R, Schumann U, et al. Factors, influencing medication errors in prehospital care: A retrospective observational study. Medicine. 2019;98(49):e18200. DOI:10.1097/MD.0000000000018200.</mixed-citation><mixed-citation xml:lang="en">Ramadanov N, Klein R, Schumann U, et al. Factors, influencing medication errors in prehospital care: A retrospective observational study. Medicine. 2019;98(49):e18200. DOI:10.1097/MD.0000000000018200.</mixed-citation></citation-alternatives></ref><ref id="cit291"><label>291</label><citation-alternatives><mixed-citation xml:lang="ru">Sada O, Melkie A, Shibeshi W. Medication prescribing errors in the medical intensive care unit of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. BMC Res Notes. 2015;8:448. DOI:10.1186/s13104-015-1435-y.</mixed-citation><mixed-citation xml:lang="en">Sada O, Melkie A, Shibeshi W. Medication prescribing errors in the medical intensive care unit of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. BMC Res Notes. 2015;8:448. DOI:10.1186/s13104-015-1435-y.</mixed-citation></citation-alternatives></ref><ref id="cit292"><label>292</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaweera A, Chung Y, Jabbarpour Y. Primary Care Physician Characteristics Associated with Prescribing Potentially Inappropriate Medication for Elderly Patients: Medicare Part D Data. J Am Board Fam Med. 2020;33(4):561-568. DOI:10.3122/jabfm.2020.04.190310.</mixed-citation><mixed-citation xml:lang="en">Jayaweera A, Chung Y, Jabbarpour Y. Primary Care Physician Characteristics Associated with Prescribing Potentially Inappropriate Medication for Elderly Patients: Medicare Part D Data. J Am Board Fam Med. 2020;33(4):561-568. DOI:10.3122/jabfm.2020.04.190310.</mixed-citation></citation-alternatives></ref><ref id="cit293"><label>293</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen A. Bad medicine: preventing drug errors in the prehospital setting. JEMS. 2008;33(10):94-100. DOI:10.1016/S0197-2510(08)70384-X.</mixed-citation><mixed-citation xml:lang="en">Nguyen A. Bad medicine: preventing drug errors in the prehospital setting. JEMS. 2008;33(10):94-100. DOI:10.1016/S0197-2510(08)70384-X.</mixed-citation></citation-alternatives></ref><ref id="cit294"><label>294</label><citation-alternatives><mixed-citation xml:lang="ru">Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724. DOI:10.1001/archinte.163.22.2716. Erratum in: Arch Intern Med. 2004;164(3):298.</mixed-citation><mixed-citation xml:lang="en">Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724. DOI:10.1001/archinte.163.22.2716. Erratum in: Arch Intern Med. 2004;164(3):298.</mixed-citation></citation-alternatives></ref><ref id="cit295"><label>295</label><citation-alternatives><mixed-citation xml:lang="ru">Lund BC, Carnaham RM, Egge JA, et al. Inappropriate prescribing predicts adverse drig events in older adults. Ann Pharmacother. 2010;44;957-963. DOI:10.1345/aph.1m657.</mixed-citation><mixed-citation xml:lang="en">Lund BC, Carnaham RM, Egge JA, et al. Inappropriate prescribing predicts adverse drig events in older adults. Ann Pharmacother. 2010;44;957-963. DOI:10.1345/aph.1m657.</mixed-citation></citation-alternatives></ref><ref id="cit296"><label>296</label><citation-alternatives><mixed-citation xml:lang="ru">Spinewine A, Schmader KE, Barber N. et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173-184. DOI:10.1016/S0140-6736(07)61091-5.</mixed-citation><mixed-citation xml:lang="en">Spinewine A, Schmader KE, Barber N. et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173-184. DOI:10.1016/S0140-6736(07)61091-5.</mixed-citation></citation-alternatives></ref><ref id="cit297"><label>297</label><citation-alternatives><mixed-citation xml:lang="ru">Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8:e019101. DOI:10.1136/bmjopen-2017-019101.</mixed-citation><mixed-citation xml:lang="en">Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8:e019101. DOI:10.1136/bmjopen-2017-019101.</mixed-citation></citation-alternatives></ref><ref id="cit298"><label>298</label><citation-alternatives><mixed-citation xml:lang="ru">Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One. 2012;7(8):e43617. DOI:10.1371/journal.pone.0043617.</mixed-citation><mixed-citation xml:lang="en">Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One. 2012;7(8):e43617. DOI:10.1371/journal.pone.0043617.</mixed-citation></citation-alternatives></ref><ref id="cit299"><label>299</label><citation-alternatives><mixed-citation xml:lang="ru">Dreischulte T, Shahid F, Muth C, et al. Prescribing Cascades: How to Detect Them, Prevent Them, and Use Them Appropriately. Dtsch Arztebl Int. 2022;119(44):745-752. DOI:10.3238/arztebl.m2022.0306.</mixed-citation><mixed-citation xml:lang="en">Dreischulte T, Shahid F, Muth C, et al. Prescribing Cascades: How to Detect Them, Prevent Them, and Use Them Appropriately. Dtsch Arztebl Int. 2022;119(44):745-752. DOI:10.3238/arztebl.m2022.0306.</mixed-citation></citation-alternatives></ref><ref id="cit300"><label>300</label><citation-alternatives><mixed-citation xml:lang="ru">Huang CH, Umegaki H, Watanabe Y et al. Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. PLoS One. 2019;14(2):e0211947. DOI:10.1371/journal.pone.0211947.</mixed-citation><mixed-citation xml:lang="en">Huang CH, Umegaki H, Watanabe Y et al. Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. PLoS One. 2019;14(2):e0211947. DOI:10.1371/journal.pone.0211947.</mixed-citation></citation-alternatives></ref><ref id="cit301"><label>301</label><citation-alternatives><mixed-citation xml:lang="ru">Fahrni ML, Azmy MT, Usir E, et al. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study. PLoS One. 2019;14(7):e0219898. DOI:10.1371/journal.pone.0219898.</mixed-citation><mixed-citation xml:lang="en">Fahrni ML, Azmy MT, Usir E, et al. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study. PLoS One. 2019;14(7):e0219898. DOI:10.1371/journal.pone.0219898.</mixed-citation></citation-alternatives></ref><ref id="cit302"><label>302</label><citation-alternatives><mixed-citation xml:lang="ru">Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900. DOI:10.1007/s40266-013-0118-4.</mixed-citation><mixed-citation xml:lang="en">Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900. DOI:10.1007/s40266-013-0118-4.</mixed-citation></citation-alternatives></ref><ref id="cit303"><label>303</label><citation-alternatives><mixed-citation xml:lang="ru">Blum MR, Sallevelt BTGM, Spinewine A, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585. DOI:10.1136/bmj.n1585. Erratum in: BMJ. 2022;379:o2859.</mixed-citation><mixed-citation xml:lang="en">Blum MR, Sallevelt BTGM, Spinewine A, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585. DOI:10.1136/bmj.n1585. Erratum in: BMJ. 2022;379:o2859.</mixed-citation></citation-alternatives></ref><ref id="cit304"><label>304</label><citation-alternatives><mixed-citation xml:lang="ru">Lavan AH, O’Mahony D, Gallagher P, et al. The effect of SENATOR (Software Engine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort — Trial Protocol. BMC Geriatrics 2019;19:40. DOI:10.1186/s12877-019-1047-9.</mixed-citation><mixed-citation xml:lang="en">Lavan AH, O’Mahony D, Gallagher P, et al. The effect of SENATOR (Software Engine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort — Trial Protocol. BMC Geriatrics 2019;19:40. DOI:10.1186/s12877-019-1047-9.</mixed-citation></citation-alternatives></ref><ref id="cit305"><label>305</label><citation-alternatives><mixed-citation xml:lang="ru">Ravn-Nielsen LV, Duckert ML, Lund ML, et al. Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(3):375-382. DOI:10.1001/jamainternmed.2017.8274.</mixed-citation><mixed-citation xml:lang="en">Ravn-Nielsen LV, Duckert ML, Lund ML, et al. Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(3):375-382. DOI:10.1001/jamainternmed.2017.8274.</mixed-citation></citation-alternatives></ref><ref id="cit306"><label>306</label><citation-alternatives><mixed-citation xml:lang="ru">Mekonnen AB, Redley B, de Courten B, et al. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4150-4172. DOI:10.1111/bcp.14870.</mixed-citation><mixed-citation xml:lang="en">Mekonnen AB, Redley B, de Courten B, et al. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4150-4172. DOI:10.1111/bcp.14870.</mixed-citation></citation-alternatives></ref><ref id="cit307"><label>307</label><citation-alternatives><mixed-citation xml:lang="ru">Liew TM, Lee CS, Goh Shawn KL et al. Potentially Inappropriate Prescribing Among Older Persons: A Meta-Analysis of Observational Studies. Ann Fam Med. 2019;17(3):257-266. DOI:10.1370/afm.2373.</mixed-citation><mixed-citation xml:lang="en">Liew TM, Lee CS, Goh Shawn KL et al. Potentially Inappropriate Prescribing Among Older Persons: A Meta-Analysis of Observational Studies. Ann Fam Med. 2019;17(3):257-266. DOI:10.1370/afm.2373.</mixed-citation></citation-alternatives></ref><ref id="cit308"><label>308</label><citation-alternatives><mixed-citation xml:lang="ru">Monégat M, Sermet C, Perronnin M, Rococo E. Polypharmacy: defnitions, measurement and stakes involved—review of the literature and measurement tests. Quest d’économie la Santé. 2014;204:1-8.</mixed-citation><mixed-citation xml:lang="en">Monégat M, Sermet C, Perronnin M, Rococo E. Polypharmacy: defnitions, measurement and stakes involved—review of the literature and measurement tests. Quest d’économie la Santé. 2014;204:1-8.</mixed-citation></citation-alternatives></ref><ref id="cit309"><label>309</label><citation-alternatives><mixed-citation xml:lang="ru">Masnoon N, Shakib S, Kalisch-Ellett L. at al. What is polypharmacy? A systematic review of definitions. BMC Geriatrics.2017;17:230. DOI:10.1186/s12877-017-0621-2.</mixed-citation><mixed-citation xml:lang="en">Masnoon N, Shakib S, Kalisch-Ellett L. at al. What is polypharmacy? A systematic review of definitions. BMC Geriatrics.2017;17:230. DOI:10.1186/s12877-017-0621-2.</mixed-citation></citation-alternatives></ref><ref id="cit310"><label>310</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В. и др. Полифармация: определение, влияние на исходы, необходимость коррекции. Рациональная Фармакотерапия в Кардиологии. 2023;19(3):254-263. DOI:10.20996/1819-6446-2023-2924.</mixed-citation><mixed-citation xml:lang="en">Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Polypharmacy: definition, impact on outcomes, need for correction. Rational Pharmacotherapy in Cardiology. 2023;19(3):254-263. (In Russ.) DOI:10.20996/1819-6446-2023-2924.</mixed-citation></citation-alternatives></ref><ref id="cit311"><label>311</label><citation-alternatives><mixed-citation xml:lang="ru">Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32-38.</mixed-citation><mixed-citation xml:lang="en">Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32-38.</mixed-citation></citation-alternatives></ref><ref id="cit312"><label>312</label><citation-alternatives><mixed-citation xml:lang="ru">Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10(1):18964. DOI:10.1038/s41598-020-75888-8.</mixed-citation><mixed-citation xml:lang="en">Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10(1):18964. DOI:10.1038/s41598-020-75888-8.</mixed-citation></citation-alternatives></ref><ref id="cit313"><label>313</label><citation-alternatives><mixed-citation xml:lang="ru">Brockhattingen KK, Anru PL, Masud T, et al. Association between number of medications and mortality in geriatric inpatients: a Danish nationwide registerbased cohort study. Eur Geriatr Med. 2020;11(6):1063-1071. DOI:10.1007/s41999-020-00390-3.</mixed-citation><mixed-citation xml:lang="en">Brockhattingen KK, Anru PL, Masud T, et al. Association between number of medications and mortality in geriatric inpatients: a Danish nationwide registerbased cohort study. Eur Geriatr Med. 2020;11(6):1063-1071. DOI:10.1007/s41999-020-00390-3.</mixed-citation></citation-alternatives></ref><ref id="cit314"><label>314</label><citation-alternatives><mixed-citation xml:lang="ru">Schöttker B, Saum K, Muhlack DC, et al. Polypharmacy and mortality: new insights from a large cohort of order adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 2017;73:1041-1048. DOI:10.1007/s00228-017-2266-7.</mixed-citation><mixed-citation xml:lang="en">Schöttker B, Saum K, Muhlack DC, et al. Polypharmacy and mortality: new insights from a large cohort of order adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 2017;73:1041-1048. DOI:10.1007/s00228-017-2266-7.</mixed-citation></citation-alternatives></ref><ref id="cit315"><label>315</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Черняева М.С., Сычев Д.А. Депрескрайбинг антигипертензивных препаратов у пациентов старших возрастных групп. Рациональная фармакотерапия в кардиологии. 2020;16(1):82-93. DOI:10.20996/1819-6446-2020-02-14.</mixed-citation><mixed-citation xml:lang="en">Ostroumova OD, Cherniaeva MS, Sychev DA. Deprescribing Antihypertensive Drugs in Patients of Older Age Groups. Rational Pharmacotherapy in Cardiology. 2020;16(1):82-93 (In Russ.) DOI:10.20996/1819-6446-2020-02-14.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
